WO2007149097A1 - Animals, cells and methods for production of detectably-labeled antibodies - Google Patents
Animals, cells and methods for production of detectably-labeled antibodies Download PDFInfo
- Publication number
- WO2007149097A1 WO2007149097A1 PCT/US2006/024592 US2006024592W WO2007149097A1 WO 2007149097 A1 WO2007149097 A1 WO 2007149097A1 US 2006024592 W US2006024592 W US 2006024592W WO 2007149097 A1 WO2007149097 A1 WO 2007149097A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- detectable
- genetically
- protein
- modified
- immune cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 27
- 241001465754 Metazoa Species 0.000 title description 22
- 238000004519 manufacturing process Methods 0.000 title description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 346
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 300
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 171
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 145
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 145
- 210000002865 immune cell Anatomy 0.000 claims abstract description 103
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 82
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 82
- 239000002157 polynucleotide Substances 0.000 claims abstract description 82
- 230000004927 fusion Effects 0.000 claims abstract description 78
- 102000039446 nucleic acids Human genes 0.000 claims description 69
- 108020004707 nucleic acids Proteins 0.000 claims description 69
- 150000007523 nucleic acids Chemical class 0.000 claims description 69
- 239000005090 green fluorescent protein Substances 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 36
- 102000036639 antigens Human genes 0.000 claims description 36
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 25
- 230000027455 binding Effects 0.000 claims description 25
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 23
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 23
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- 108010090227 Immunoglobulin kappa-Chains Proteins 0.000 claims description 17
- 108010004020 Immunoglobulin lambda-Chains Proteins 0.000 claims description 17
- 102000012960 Immunoglobulin kappa-Chains Human genes 0.000 claims description 16
- 238000010791 quenching Methods 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 230000003053 immunization Effects 0.000 claims description 11
- 230000000171 quenching effect Effects 0.000 claims description 11
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 10
- 108090001008 Avidin Proteins 0.000 claims description 9
- 229960002685 biotin Drugs 0.000 claims description 9
- 235000020958 biotin Nutrition 0.000 claims description 9
- 239000011616 biotin Substances 0.000 claims description 9
- 238000002649 immunization Methods 0.000 claims description 9
- 108091035707 Consensus sequence Proteins 0.000 claims description 8
- 108010090804 Streptavidin Proteins 0.000 claims description 8
- 230000006287 biotinylation Effects 0.000 claims description 8
- 238000007413 biotinylation Methods 0.000 claims description 8
- 230000021615 conjugation Effects 0.000 claims description 8
- 230000017730 intein-mediated protein splicing Effects 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 229920002101 Chitin Polymers 0.000 claims description 6
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 102000006830 Luminescent Proteins Human genes 0.000 claims description 5
- 108010047357 Luminescent Proteins Proteins 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 238000012239 gene modification Methods 0.000 abstract description 8
- 230000005017 genetic modification Effects 0.000 abstract description 8
- 235000013617 genetically modified food Nutrition 0.000 abstract description 8
- 108700005091 Immunoglobulin Genes Proteins 0.000 abstract description 6
- 230000003248 secreting effect Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 198
- 102000004196 processed proteins & peptides Human genes 0.000 description 75
- 229920001184 polypeptide Polymers 0.000 description 42
- 241000124008 Mammalia Species 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 18
- 230000002163 immunogen Effects 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 102000005936 beta-Galactosidase Human genes 0.000 description 8
- 108010005774 beta-Galactosidase Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102220566468 GDNF family receptor alpha-1_S65G_mutation Human genes 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 102000034287 fluorescent proteins Human genes 0.000 description 6
- 108091006047 fluorescent proteins Proteins 0.000 description 6
- 108010054624 red fluorescent protein Proteins 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 241000283074 Equus asinus Species 0.000 description 5
- 102220566479 GDNF family receptor alpha-1_S72A_mutation Human genes 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 229930193140 Neomycin Natural products 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 241000243290 Aequorea Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102220567280 GDNF family receptor alpha-1_T203F_mutation Human genes 0.000 description 2
- 102220566483 GDNF family receptor alpha-1_V68L_mutation Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- MIAKOEWBCMPCQR-YBXAARCKSA-N (2s,3r,4s,5r,6r)-2-(4-aminophenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C1=CC(N)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MIAKOEWBCMPCQR-YBXAARCKSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical class NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 101000997963 Aequorea victoria Green fluorescent protein Proteins 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102220566687 GDNF family receptor alpha-1_F64L_mutation Human genes 0.000 description 1
- 102220566467 GDNF family receptor alpha-1_S65A_mutation Human genes 0.000 description 1
- 102220566451 GDNF family receptor alpha-1_Y66H_mutation Human genes 0.000 description 1
- 102220486246 Glucosidase 2 subunit beta_S65V_mutation Human genes 0.000 description 1
- 101000840267 Homo sapiens Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 102220615016 Transcription elongation regulator 1_S65C_mutation Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- -1 aromatic amino acid Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220243291 rs1555194026 Human genes 0.000 description 1
- 102200142969 rs398124653 Human genes 0.000 description 1
- 102200089551 rs5030826 Human genes 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
Definitions
- the invention is directed to methods for obtaining detectably-labeled antibodies to any antigen by using genetically-modified mammals which express at least one detectably-labeled antibody molecule component.
- Antibodies are widely used for diagnostic and research purposes for localizing an antigen within a cell, tissue, or other biological sample.
- cells are usually first exposed to a primary antibody which is specific for the desired target antigen but not directly detectable.
- the primary antibody is detected with a labeled secondary antibody which recognizes the primary antibody.
- This procedure is somewhat cumbersome and may result in undesirable background staining due to non-specific reactivity of the secondary antibody.
- the relationship between the protein and the detectable signal is extremely non-linear, with a limited dynamic range between the minimal detectable signal and saturation.
- the primary antibodies in order to visualize two or more antigens, the primary antibodies must be from two different species such that each secondary antibody is not cross- reactive; expensive species-specific secondary antibodies must therefore be used for each primary antibody.
- the primary antibodies With advances in optical and digital imaging and detection, multiply-labeled samples and simultaneous detection of several analytes is possible, yet the aforementioned biological limitations do not permit full advantage to be taken of these advances.
- monoclonal antibodies are generated typically only in mice and rats, in conventional dual or triple labeling, only one antibody can be monoclonal. This is often a limiting important restriction.
- the invention is directed to a genetically-modified non-human mammal capable of expressing at least one chimeric immunoglobulin gene comprising at least one detectable protein or peptide fused with a gene expressing an immunoglobulin component.
- the immunoglobulin component may be selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof.
- the antibodies secreted by the immune cells of the genetically-modified mammal comprise said at least one detectable protein or peptide.
- the immunoglobulin heavy chain gene may be IgG, IgM, IgD or IgA.
- the immunoglobulin component may be a complete immunoglobulin molecule comprising two heavy and two light chains.
- the at least one detectable peptide or protein is present at the C- terminus of the gene product of the fusion polynucleotide; preferably, the at least one detectable peptide or protein present at the C-terminus of the gene product of the fusion polynucleotide is located in exon Gl.
- the at least one detectable peptide or protein is present at the C-terminus of the gene product of the fusion polynucleotide with a flexible linker peptide located between the detectable peptide or protein and the immunoglobulin component.
- the at least one detectable peptide or protein present at the C-terminus of the gene product of said fusion polynucleotide with a flexible linker located between the detectable peptide or protein and the immunoglobulin component is located in exon Gl .
- the invention provides a genetically-modified non-human mammal containing a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least one detectable protein, wherein said non-human mammal is capable of expressing at least one detectable protein fused with said immunoglobulin component wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises said at least one detectable protein.
- the invention is directed to a genetically-modified non- human mammal containing a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin molecule comprising two heavy chains and two light chains, and a nucleic acid encoding at least one detectable protein, wherein said non-human mammal is capable of expressing said at least one detectable protein fused with said immunoglobulin molecule wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises said at least one detectable protein.
- the invention is directed to a genetically-modified non- human mammal containing a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least two detectable proteins, wherein said non-human mammal is capable of expressing at least two detectable proteins fused with said immunoglobulin component wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises said at least two detectable proteins.
- the invention is directed to a genetically-modified non- human mammal containing a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin molecule comprising two heavy chains and two light chains, and a nucleic acid encoding at least two detectable proteins, wherein said non-human mammal is capable of expressing at least two detectable proteins fused with said immunoglobulin molecule wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises said at least two detectable proteins.
- the genetically-modified non-human mammal is a non- domestic animal selected from a rodent, a rabbit, a goat, a pig, a horse, a cow, a donkey, a monkey and a sheep.
- the non-human mammal is a mouse or a rat.
- the non-human mammal may be selected from a domestic mammal such as, but not limited to, a dog or cat.
- the immunoglobulin molecule secreted by immune cells of the above-mentioned genetically-modified mammal comprises at least one detectable protein or peptide in the heavy chain of the immunoglobulin molecule.
- the immunoglobulin molecule secreted by immune cells of the genetically-modified mammal comprises at least one detectable protein or peptide in the light chain of said immunoglobulin molecule.
- the immunoglobulin molecule secreted by immune cells of the genetically-modified mammal comprises at least one detectable protein or peptide in the heavy chain and at least one detectable protein or peptide in the light chain of said immunoglobulin molecule.
- the at least one detectable label may be found in both of the light chains and/or in both of the heavy chains of the immunoglobulin molecule.
- the immunoglobulin molecule secreted by immune cells of the above-mentioned genetically-modified mammal comprises at least two detectable proteins or peptides in the heavy chain of the immunoglobulin molecule.
- the immunoglobulin molecule secreted by immune cells of the genetically-modified mammal comprises at least two detectable proteins or peptides in the light chain of said immunoglobulin molecule.
- the immunoglobulin molecule secreted by immune cells of the genetically-modified mammal comprises at least two detectable proteins or peptides in the heavy chain and at least two detectable proteins or peptides in the light chain of said immunoglobulin molecule.
- the at least two detectable labels may be found in both of the light chains and in both of the heavy chains of the immunoglobulin molecule.
- at least one of the aforementioned detectable proteins or polypeptides is an autofluorescent protein or peptide, a visibly-detectable protein or peptide, an enzymatically active protein or peptide, a protein or peptide capable of interacting with another molecule to produce a detectable product, or any combination thereof.
- the protein capable of interacting with another molecule to produce a detectable product is selected from, but not limited to, the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation or a chitin-binding domain, or any combination thereof.
- the protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of the detectable product, or to add an additional fluorophore or to add a therapeutic molecule.
- the detectable protein or polypeptide is capable of quenching or modulating fluorescence.
- Non-limiting examples of autofluorescent proteins or peptides include green fluorescent protein, red fluorescent protein, a fluorescent analog, or fragment of any of the foregoing, or a luminescent protein.
- the at least one detectable protein is a combination of an autofluorescent protein or peptide and an enzymatically-active protein or peptide, such as but not limited to a combination of green fluorescent protein and alkaline phosphatase.
- a genetically-modified immune cell which is capable of expressing at least one chimeric immunoglobulin gene comprising at least one detectable protein or peptide fused with a gene expressing an immunoglobulin component.
- the immunoglobulin component may be selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof.
- Antibodies secreted by the genetically-modified immune cell comprise the at least one detectable protein or peptide.
- the immunoglobulin heavy chain gene may be IgG, IgM, IgD or IgA.
- the immunoglobulin component may be a complete immunoglobulin molecule comprising two heavy and two light chains.
- the at least one detectable peptide or protein is present at the C-terminus of the gene product of the fusion polynucleotide; preferably, the polynucleotide encoding the at least one detectable peptide or protein present at the C-terminus of the gene product of said fusion polynucleotide is located in exon Gl.
- the at least one detectable peptide or protein present at the C-terminus of the gene product of said fusion polynucleotide has a flexible linker peptide between the detectable peptide or protein and the immunoglobulin component; preferably, the polynucleotide encoding the at least one detectable peptide or protein present at the C-terminus of the gene product of said fusion polynucleotide with a flexible linker therebetween is located in exon Gl .
- the invention provides a genetically-modified immune cell having a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, a nucleic acid encoding at least one detectable protein, and a nucleic acid encoding a flexible linker peptide located between the nucleic acid encoding the immunoglobulin component and the nucleic acid encoding the at least one detectable protein, and wherein said immune cell is capable of expressing at least one detectable protein fused with said immunoglobulin molecule, with the flexible linker peptide between the immunoglobulin molecule and the at least one detectable protein, wherein antibodies secreted by said genetically- modified immune cell comprise said at least one detectable protein.
- the invention provides a genetically-modified immune cell having a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin molecule comprising two heavy and two light chains, a nucleic acid encoding at least one detectable protein, and a nucleic acid encoding a flexible linker peptide located between the nucleic acid encoding the immunoglobulin molecule comprising two heavy and two light chains and the nucleic acid encoding the at least one detectable protein, and wherein said immune cell is capable of expressing at least one detectable protein fused with said immunoglobulin molecule, with the flexible linker peptide between the immunoglobulin molecule and the at least one detectable protein, wherein antibodies secreted by said genetically-modified immune cell comprise said at least one detectable protein.
- the invention provides a genetically-modified immune cell having a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, a nucleic acid encoding at least two detectable proteins, and a nucleic acid encoding a flexible linker peptide located between the nucleic acid encoding the immunoglobulin component and the nucleic acid encoding the at least two detectable proteins, and wherein said immune cell is capable of expressing at least two detectable proteins fused with said immunoglobulin component, with the flexible linker peptide between the immunoglobulin component and the at least two detectable proteins, wherein antibodies secreted by said genetically-modified immune cell comprise said at least two detectable proteins.
- the invention provides a genetically-modified immune cell having a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin molecule comprising two heavy and two light chains, a nucleic acid encoding at least two detectable proteins, and a nucleic acid encoding a flexible linker peptide located between the nucleic acid encoding the immunoglobulin molecule and the nucleic acid encoding the at least two detectable proteins, and wherein said immune cell is capable of expressing at least two detectable proteins fused with said immunoglobulin molecule, with the flexible linker peptide between the immunoglobulin molecule and the at least two detectable proteins, wherein antibodies secreted by said genetically-modified immune cell comprise said at least two detectable proteins.
- the immunoglobulin molecule secreted by the aforementioned immune cell may comprise at least one detectable protein or peptide in the heavy chain of the immunoglobulin molecule, or it may comprise at least one detectable protein or peptide in the light chain of said immunoglobulin molecule.
- the immunoglobulin molecule secreted by the genetically-modified immune cells described above comprises at least one detectable protein or peptide in the heavy chain and at least one detectable protein or peptide in the light chain of the immunoglobulin molecule.
- the at least one detectable label may be found in one or in both of the light chains and in one or in both of the heavy chains of the immunoglobulin molecule or any combination thereof.
- the immunoglobulin molecule secreted by immune cells of the genetically-modified mammal comprises at least two detectable proteins or peptides in one or both of the heavy chains and at least two detectable proteins or peptides in one or both of the light chains of said immunoglobulin molecule.
- the aforementioned genetically-modified immune cell may have at least one detectable protein or polypeptide that is capable of quenching or modulating fluorescence; or the protein or peptide is an autofluorescent protein or peptide, a visibly-detectable protein or peptide, an enzymatically active protein or peptide, a protein or peptide capable of interacting with another molecule to produce a detectable product, or any combination thereof.
- the protein capable of interacting with another molecule to produce a detectable product is selected from the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, or a chitin-binding domain, a consensus sequence for biotinylation, or any combination thereof.
- the protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of the detectable product.
- the at least one detectable protein is an autofluorescent protein or peptide, it may be, by way of non-limiting example, green fluorescent protein, red fluorescent protein, or a fluorescent analog or fragment of any of the foregoing.
- the at least one detectable protein is a combination of an autofluorescent protein or peptide and an enzymatically-active protein or peptide, such as but not limited to a combination of green fluorescent protein and alkaline phosphatase.
- the at least one or at least two detectable proteins are present at the C-terminus of the gene product of the fusion polynucleotide in the genetically- modified immune cell.
- the nucleic acid encoding the at least one or at least two detectable proteins present at the C-terminus of the gene product of the fusion polynucleotide is located in exon Gl.
- the antibody secreted by the immune cell comprises at least two detectable proteins in the heavy chain of said antibody.
- the antibody secreted by the genetically-modified immune cell comprises at least two detectable proteins in the light chain of said antibody.
- the antibody secreted by the genetically-modified immune cell comprises at least two detectable proteins in the heavy chain and at least two detectable proteins in the light chain of the antibody.
- the immunoglobulin heavy chain is selected from the group consisting of IgG, IgM, IgD and IgA.
- the invention is also directed to a hybridoma generated from any of the genetically- modified immune cells as mentioned above.
- the invention is directed to a chimeric, detectably-labeled immunoglobulin molecule comprising at least one detectable protein or peptide fused with an immunoglobulin component.
- the immunoglobulin component may be selected from the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, or any combination thereof.
- the immunoglobulin component may be a complete immunoglobulin molecule comprising two heavy chains and two light chains.
- the at least one detectable peptide or protein maybe present at the C-terminus of the gene product of said fusion polynucleotide, preferably located in exon Gl .
- a flexible linker peptide may be provided therebetween.
- a polynucleotide encoding said at least one detectable peptide or protein present at the C-terminus of the gene product of said fusion polynucleotide with a flexible linker therebetween is located in exon Gl.
- the chimeric, detectably-labeled immunoglobulin molecule may have an immunoglobulin heavy chain gene is selected from IgG, IgM, IgD and IgA.
- At least one detectable protein or peptide may be present in the heavy chain of said immunoglobulin molecule, the at least one detectable protein or peptide may be present in the light chain of said immunoglobulin molecule, or, in a further embodiment, the at least one detectable protein or peptide may be present in the heavy chain and at least one detectable protein or peptide in the light chain of said immunoglobulin molecule. In another particular embodiment, the at least one detectable label may be found in both of the light chains and in both of the heavy chains of the immunoglobulin molecule.
- the aforementioned chimeric, detectably-labeled immunoglobulin molecule may have at least one detectable protein or polypeptide that is capable of quenching or modulating fluorescence; or, the at least one detectable protein or peptide is an autofiuorescent protein or peptide, a visibly-detectable protein or peptide, an enzymatically active protein or peptide, a protein or peptide capable of interacting with another molecule to produce a detectable product, or any combination thereof.
- the protein capable of interacting with another molecule to produce a detectable product is selected from the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation, or a chitin-binding domain, or any combination thereof.
- the protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of the detectable product.
- the at least one detectable protein is an autofluorescent protein or peptide, such as but not limited to green fluorescent protein, red fluorescent protein, or a fluorescent analog or fragment of any of the foregoing.
- the at least one detectable protein may be a combination of an autofluorescent protein or peptide and an enzymatically-active protein or peptide, such as but not limited to a combination of green fluorescent protein and alkaline phosphatase.
- the invention provides a genetically-modified non- human mammal whose genome comprises a fusion polynucleotide, wherein the fusion polynucleotide comprises a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least one detectable protein, wherein the non-human mammal is capable of expressing the at least one detectable protein fused with the immunoglobulin component and wherein an antibody secreted by an immune cell of the genetically-modified non-human mammal comprises the at least one detectable protein.
- the fusion polynucleotide comprises a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof
- the invention provides a genetically-modified non- human mammal whose genome comprises a fusion polynucleotide, wherein the fusion polynucleotide comprises a nucleic acid encoding an immunoglobulin molecule comprising two heavy and two light chains, and a nucleic acid encoding at least one detectable protein, wherein the non-human mammal is capable of expressing the at least one detectable protein fused with the immunoglobulin molecule and wherein an antibody secreted by an immune cell of the genetically-modified non-human mammal comprises the at least one detectable protein.
- the invention provides a genetically-modified non- human mammal whose genome comprises a fusion polynucleotide, wherein the fusion polynucleotide comprises a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least two detectable proteins, wherein the non-human mammal is capable of expressing the at least two detectable proteins fused with the immunoglobulin component and wherein an antibody secreted by an immune cell of the genetically-modified non-human mammal comprises the at least two detectable proteins.
- the fusion polynucleotide comprises a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof
- the invention provides a genetically-modified non- human mammal whose genome comprises a fusion polynucleotide, wherein the fusion polynucleotide comprises a nucleic acid encoding an immunoglobulin molecule comprising two heavy and two light chains, and a nucleic acid encoding at least two detectable proteins, wherein the non-human mammal is capable of expressing the at least two detectable proteins fused with the immunoglobulin molecule and wherein an antibody secreted by an immune cell of the genetically-modified non-human mammal comprises the at least two detectable proteins.
- the at least one or at least two detectable labels may be present in one or both of the heavy and light chains.
- the genetically-modified non-human mammal is a non-domestic animal selected from a rodent, a rabbit, a goat, a pig, a horse, a cow, a donkey, a monkey and a sheep.
- the non-human mammal is a mouse.
- the non-human mammal is a mouse or rat.
- the non-human mammal may be selected from a domestic mammal such as, but not limited to, a dog or cat.
- the at least two detectable proteins encoded by the fusion polynucleotide are present at the C-terminus of the gene product of the fusion polynucleotide.
- the nucleic acid encoding the at least two detectable proteins present at the C-terminus of the gene product of the fusion polynucleotide is located in exon Gl .
- the at least two detectable proteins are present at the C- terminus of the gene product of the fusion polynucleotide with a flexible linker peptide located between the at least two detectable proteins and the immunoglobulin component.
- the antibody secreted by an immune cell of the genetically-modified mouse comprises at least two detectable proteins in the heavy chain of the antibody. In yet another particular embodiment, the antibody secreted by an immune cell of the genetically-modified mouse comprises at least two detectable proteins in the light chain of the antibody. In yet another particular embodiment, the antibody secreted by an immune cell of the genetically-modified mouse comprises at least two detectable proteins in the heavy chain and at least two detectable proteins in the light chain of the antibody. In yet another particular embodiment, the immunoglobulin heavy chain is selected from the group consisting of IgG, IgM, IgD and IgA.
- the at least one of the at least two detectable proteins is capable of quenching fluorescence.
- at least one of the at least two detectable proteins is an auto fluorescent protein, a visibly-detectable protein, an enzymatically active protein, or a protein capable of interacting with another molecule to produce a detectable product, or any combination thereof.
- the protein capable of interacting with another molecule to produce a detectable product is selected from the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation or a chitin-binding domain, or any combination thereof.
- the protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of the detectable product, or to add an additional fluorophore or to add a therapeutic molecule.
- the at least one of the at least two detectable proteins is an autofluorescent protein.
- autofluorescent proteins or peptides include green fluorescent protein, cyan fluorescent protein, yellow fluorescent protein, red fluorescent protein, and a fluorescent analog or fragment of any of the foregoing.
- the autofluorescent protein is green fluorescent protein.
- the at least one detectable protein is a combination of an autofluorescent protein and an enzymatically-active protein.
- the at least one detectable protein is a combination of green fluorescent protein and alkaline phosphatase.
- the invention provides a genetically-modified non-human mammal capable of producing a detectably-labeled antibody in response to immunization by an antigen, the genome of said non-human mammal comprising a fusion polynucleotide comprising a nucleic acid encoding at least one detectable protein and a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, wherein an antibody secreted by an immune cell of said genetically- modified non-human mammal comprises one detectable protein.
- the invention provides a genetically-modified non-human mammal capable of producing a detectably-labeled antibody in response to immunization by an antigen, the genome of said non-human mammal comprising a fusion polynucleotide comprising a nucleic acid encoding at least one detectable protein and a nucleic acid encoding an immunoglobulin molecule comprising two heavy chains and two light chains, wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises one detectable protein.
- the invention is also directed to a genetically-modified mammal capable of producing a detectably-labeled immunoglobulin in response to immunization by an antigen, the genome of the mammal comprising at least one fusion polynucleotide consisting of a polynucleotide sequence encoding at least two detectable proteins or peptides fused with a the kappa immunoglobulin light chain gene, the lambda immunoglobulin light chain gene, an immunoglobulin heavy chain gene, or any combination thereof, wherein antibodies secreted by immune cells of the genetically-modified mammal comprise the at least two detectable proteins or peptides.
- the genetically-modified mammal is a mouse, although other genetically-modified mammals may be selected from a goat, a pig, a horse, a cow, a dog, a cat, a donkey, a monkey and a rabbit, and other rodents, including rats, and any other domestic or non-domestic animal.
- the invention is also directed to a genetically-modified mammal capable of producing a detectably-labeled immunoglobulin in response to immunization by an antigen, the genome of the mammal comprising at least one fusion polynucleotide consisting of a polynucleotide sequence encoding at least two detectable proteins or peptides fused with an immunoglobulin molecule comprising two heavy and two light chains, wherein antibodies secreted by immune cells of the genetically-modified mammal comprise the at least two detectable proteins or peptides.
- the genetically-modified mammal is a mouse, although other genetically-modified mammals may be selected from a goat, a donkey, a monkey, a pig, a horse, a cow, a dog, a cat, a rabbit, and other rodents, including rats, and any other domestic or non-domestic animal.
- the invention provides a hybridoma capable of producing an antibody having at least two detectable proteins as described herein.
- the invention is directed to a chimeric, detectably-labeled immunoglobulin molecule comprising at least one fluorescent protein or peptide and at least one fluorescence-quenching or -modulating protein or peptide fused with a component of the immunoglobulin molecule independently selected from either the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, or any combination thereof.
- the invention provides a chimeric, detectably-labeled immunoglobulin molecule comprising at least two detectable proteins or peptides fused with the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, or any combination thereof.
- the chimeric, detectably-labeled immunoglobulin molecule is encoded by a fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least two detectable peptides or proteins that are present at the C-terminus of the gene product of the fusion polynucleotide.
- the nucleic acid encoding the at least two detectable peptides or proteins present at the C terminus of the gene product of the fusion polynucleotide is located in exon Gl .
- the at least two detectable peptides or proteins that are present at the C- terminus of the gene product of a fusion polynucleotide contain a flexible linker peptide located between the at least two detectable proteins and the immunoglobulin component.
- the immunoglobulin heavy chain is selected from the group consisting of IgG, IgM, IgD and IgA.
- the chimeric, detectably-labeled immunoglobulin may have at least two detectable proteins or peptides in the heavy chain of the immunoglobulin molecule. In yet another particular embodiment, the chimeric, detectably-labeled immunoglobulin may have at least two detectable proteins or peptides in the light chain of the immunoglobulin molecule, hi yet another particular embodiment, the chimeric, detectably- labeled immunoglobulin may have at least two detectable proteins or peptides in the heavy chain and at least two detectable proteins or peptides in the light chain of the immunoglobulin molecule.
- the aforementioned chimeric, detectably-labeled immunoglobulin molecule may have one of the at least two detectable proteins or peptides that is capable of quenching fluorescence.
- the chimeric, detectably-labeled immunoglobulin molecule may have at least one of the at least two detectable proteins or peptides that is an autofluorescent protein or peptide, a visibly-detectable protein or peptide, an enzymatically active protein or peptide, or a protein or peptide capable of interacting with another molecule to produce a detectable product, or an analog or fragment thereof.
- the protein capable of interacting with another molecule to produce a detectable product is selected from the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation, or a chitin- binding domain, or any combination thereof.
- the protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of the detectable product, or to add an additional fluorophore or to add a therapeutic molecule.
- the chimeric, detectably-labeled immunoglobulin molecule may have at least one of the at least two detectable proteins that is an autofluorescent protein or peptide.
- the chimeric, detectably-labeled immunoglobulin molecule may have at least one of the at least two autofluorescent proteins or peptides selected from the group consisting of green fluorescent protein, red fluorescent protein, and a fluorescent analog or fragment of any of the foregoing.
- the autofluorescent protein may be green fluorescent protein.
- the at least one of the at least two detectable proteins may be a combination of an autofluorescent protein or peptide and an enzymatically-active protein or peptide.
- the at least one of the two detectable proteins maybe a combination of green fluorescent protein and alkaline phosphatase.
- the present invention provides a method for producing a quantity of detectably-labelled polyclonal antibodies by carrying out at least the steps of a) providing a genetically-modified mammal as described hereinabove; b) immunizing the genetically-modified mammal with a preselected immunogen, wherein the genetically-modified mammal generates antibodies to the immunogen, wherein antibodies secreted by immune cells of the genetically- modified mammal comprise the at least one detectable protein or peptide; and c) isolating the detectably-labelled antibodies from the genetically-modified mammal.
- the invention is also directed to a method for producing a quantity of detectably-labelled monoclonal antibodies comprising the steps of a) preparing a genetically-modified mammal in accordance with the above description; b) immunizing the genetically-modified mammal with a preselected immunogen, wherein immune cells of the genetically-modified mammal generate antibodies to the immunogen, wherein antibodies secreted by the immune cells comprise the at least one detectable protein or peptide; c) immortalizing antibody-producing immune cells isolated from the genetically- modified mammal; d) selecting immortalized immune cells isolated from the genetically-modified mammal that secrete antibodies specific to the immunogen; and e) preparing a quantity of detectably-labeled monoclonal antibodies from the selected immune cells.
- Figure 1 shows the beta-galactosidase-binding activity of a chimeric fusion immunoglobulin secreted from 293T cells transfected with nucleic' acid encoding a green- fluorescent-protein-labeled heavy immunoglobulin (IgG2) chain and a green-fluorescent-protein- labeled light (kappa) chain hybrid anti-beta-galactosidase immunoglobulin.
- IgG2 green- fluorescent-protein-labeled heavy immunoglobulin
- kappa green-fluorescent-protein- labeled light
- Figures 2 A-B show the fluorescence of antibodies in serum from kappa-GFP knock-in mice bound to Protein A/G beads, as compared to those from wild-type mice.
- Figure 3 A-B demonstrate using PCR amplification that mice of the invention may be homozygous or heterozygous for the kappa-GFP gene, using kappa light chain primers ( Figure 3A). Use of GFP primers ( Figure 3B) confirm the presence or absence of the GFP insert.
- the inventors herein have discovered a novel and facile method for preparing useful quantities of detectably-labeled polyclonal or monoclonal antibodies to any preselected immunogen.
- the method spares the need to perform any modification of the immunogen- specific (primary) antibody to provide a detectable label thereon, such as conjugation to a fluorophore or enzyme, as the detectably-labeled antibodies of the invention are inherently labeled as they are expressed and secreted from genetically-modified immune system cells.
- the invention provides genetically-modified animals and immune cells from such animals in which the constant region of the heavy and/or the light chain components of the antibodies produced by the animals or cells is fused with a detectable polypeptide, such as a fluorescent polypeptide, these fusion protein(s) resulting from the expression of a genetic modification of the heavy and/or light chain genes wherein the polynucleotide encoding the detectable label is incorporated into the respective genes.
- a detectable polypeptide such as a fluorescent polypeptide
- Such genetically-modified animals or cells are provided such that any antibody expressed and secreted by the animal or cell comprises at least one labeled constant region.
- the mere induction of a humoral immune response generates the desired detectably-labeled antibody.
- the detectable labels of the invention may be polypeptides, such as proteins or peptides, and they may be introduced into the genome of a mammalian organism by such methods as homologous recombination and transfection, but such methods are not intended to be limiting whatsoever, and one of skill in the art may prepare the construct(s) and modified cells in any appropriate manner. Embryonic stem cells may be so modified such that the genome of the animal resulting therefrom comprises the genetic modification. Several examples provided below are for illustrative purposes only.
- detectable refers to anything that allows the presence of the antibody to be detected. Any such molecule that allows the detection of the antibody should have no effect on the ability of the animal to generate a full spectrum antibody response. Any such molecule that allows for the detection of the antibody should have no effect on the synthesis and assembly of the four molecules that form the complete antibody (the two heavy and two light chains). Any such molecule that allows for the detection of the antibody should have no effect on the transport of the assembled antibody out of the cell. Any such molecule that allows for the detection of the antibody should have no effect on the affinity of the antibody for its target.
- the detectable polypeptide may be, by way of non-limiting example, a fluorescent polypeptide, a luminescent polypeptide, a visibly-colored polypeptide, a polypeptide with enzymatic activity, or a polypeptide capable of interacting with or binding to another molecule to produce a detectable product.
- the label is one that requires no direct interaction or further sample processing for detectability, and thus is detectable by the application of exogenous methods such as absorbance of light, fluorescence, etc.
- the label is a fluorescent polypeptide.
- the label is green fluorescent protein and its polypeptide relatives.
- a plurality of detectable labels may be present in the antibodies produced by the animals or cells of the invention.
- a fluorescent label and an enzyme label may be appended in tandem to the C-terminus of an immunoglobulin heavy chain gene, such that the resulting expressed and assembled immunoglobulin molecule is detectable both by fluorescence and by histochemistry, by use of a fluorigenic and chromogenic/precipitating substrate of the enzyme, respectively.
- the antibody is detectable fluorometrically and by Western blot.
- the antibody is detectable fluorometrically and a conjugation tag is used to add a therapeutic agent.
- either or both the heavy and light chain constant regions may be independently modified as described herein, both with the same single or plurality of labels, or, for example, the heavy chain with a fluorescent label and the light chain with an enzyme label.
- These particular examples of multiple labels on multiple sites of the antibodies are merely illustrative of the range of directly-labeled antibodies that the skilled artisan may be directed to prepare following the teachings herein, and any particular example or embodiment is not intended to be limiting whatsoever.
- fluorescent polypeptides include but are not limited to green fluorescent protein and other related polypeptide fluorophores which may produce other colors; the availably of individually-detectable primary antibodies in a mixture allows for the simultaneous localization or quantitation of multiple target antigens or analytes in a biological sample.
- One particular embodiment of the invention utilizes the green fluorescent protein of Aequorea victoria. A cDNA for the protein has been cloned (D. C. Prasher et al., "Primary structure of the Aequorea victoria green-fluorescent protein," Gene (1992) 111:229-33.).
- GFP Aequorea green fluorescent protein
- GFP is a stable, proteolysis-resistant single chain of 238 residues and has two absorption maxima at around 395 and 475 nm; Excitation at the primary absorption peak of 395 nm yields an emission maximum at 508 nm with a quantum yield of 0.72-0.85 (O. Shimomura and F. H. Johnson J. Cell. Comp. Physiol. 59:223 (1962); J. G. Morin and J. W. Hastings, J. Cell. Physiol. 77:313 (1971); H. Morise et al. Biochemistry 13:2656 (1974); W. W. Ward Photochem. Photobiol. Reviews (Smith, K. C.
- Mutants of GFP are embraced herein as they provide certain other characteristics, such as mutation of Serine 65 to Thr (S65T) simplifies the excitation spectrum to a single peak at 488 nm of enhanced amplitude (R. Heim et al. Nature 373:664-665 (1995)), which no longer gives signs of conformational isomers (A. B. Cubitt et al. Trends Biochem. Sci. 20:448-455 (1995)).
- S65T Serine 65 to Thr
- 6,077,707 describes a nucleic acid molecule comprising a nucleotide sequence encoding a functional engineered fluorescent protein whose amino acid sequence is substantially identical to the amino acid sequence of Aequorea green fluorescent protein but differs by at least a substitution at T203 and, in particular, T203X, wherein X is an aromatic amino acid selected from H, Y, W or F.
- the amino acid sequence further comprises a substitution at S65, wherein the substitution is selected from S65G, S65T, S65A, S65L, S65C, S65V and S65I.
- the amino acid sequence differs by no more than the substitutions S65T/T203H; S65T/T203Y; S72A/F64L/S65G/T203Y; S65G/V68L/Q69K/S72A/T203Y; S72A/S65G/V68L/T203Y; S65G/S72A/T203Y; or S65G/S72A/T203W.
- the nucleotide sequence encoding the protein differs from the nucleotide sequence of native green fluorescent protein by the substitution of at least one codon encoding an amino acid substitution at L42, V61, T62, V68, Q69, Q94, N121, Y145, H148, V150, F165, 1167, Ql 83, Nl 85, L220, E222 (not E222G), or V224.
- the amino acid substitution is: L42X, wherein X is selected from C, F, H, W and Y, V61 X, wherein X is selected from F, Y, H and C, T62X, wherein X is selected from A, V, F, S, D, N, Q, Y, H and C, V68X, wherein X is selected from F, Y and H, Q69X, wherein X is selected from K, R, E and G, Q94X, wherein X is selected from D, E, H, K and N, N121X, wherein X is selected from F, H, W and Y, Y145X, wherein X is selected from W, C, F, L, E, H, K and Q, H148X, wherein X is selected from F, Y, N, K, Q and R, Vl 5OX, wherein X is selected from F, Y and H, F165X, wherein X is selected from H, Q, W and Y, Vl 5
- fluorescent protein is red fluorescent protein from coral (Matz et. al, 1999, Nature Biotechnology 17:969). Fluorescent peptides or fluorescent protein fragments of these and other fluorescent proteins are also embraced herein.
- polypeptide labels capable of being detected include those containing four cysteines at the i, i+1, i+4, and i+5 positions (i.e., WEAAAREACCRECCARA (SEQ ID NO: I)). These peptides will bind specifically to the fluorescein derivative 4',5'-bis(l,3,2- dithioarsolan-2-yl)fluorescein (FLASH), which is non-fluorescent until bound.
- polypeptides capable of being detected by enzymatic activity include various enzymes and catalytic polypeptide fragments thereof.
- Particularly preferred enzymatic labels include those which are able to produce a detectable color or fluorophore in a single step requiring a minimum or reagents, such as alkaline phosphatase, which can cleave a chromogenic substrate, such as p-nitrophenyl phosphate, or a fluorigenic substrate, such as ECF substrate (Amersham/Pharmacia); and a fluorigenic horseradish peroxidase substrate, FluoroBlot (Pierce Chemical Co.).
- Another example is a fluorescent beta-galactosidase substrate that can be used in live cells and is 100-fold more sensitive than GFP (Zlokarnik et. al., 1988, Science 279:85).
- the skilled artisan by the teachings herein will be amply aware of polynucleotides that may be fused to the immunoglobulin constant region(s) and upon expression produce an enzymatically-active fusion polypeptide comprising the immunoglobulin heavy and/or light chain.
- Such labels may also result in the precipitation of a substrate, for histochemical localization of the antibody, or the label may interact with another detectable component, ands thus be, for example, an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation or a chitin-binding domain.
- the antibody molecule is composed of two heavy chains and two light chains. Each chain has a two identical variable regions which bind antigen, and a constant region. The N-terminus of both chains is part of the variable region and the C-terminus is part of the constant region.
- the genomic organization of heavy chain contains a number of repeats of V, D, and J regions upstream of several constant regions.
- the different constant regions define the eventual antibody class (e.g., IgGl, IgG2a, IgA, etc).
- IgGl IgG2a
- IgA IgA
- a single V, D, and J are joined to form a single exon.
- class switching a process called "class switching”.
- Each constant region contains a number of exons.
- the VDJ and constant regions are spliced into the mature mRNA.
- a polynucleotide encoding the detectable polypeptide is inserted into the constant region, or preferably, is appended to portion of the gene resulting in the expression of the fused polypeptide label on the C-terminus of the constant region of the light and/or heavy chains, optionally with a flexible linker peptide.
- mice There are two classes of light chains, kappa and lambda. In mice, kappa comprises 95% of antibodies, lambda 5%. Furthermore, there are two forms of each class of the heavy chain — a secreted and a membrane bound form.
- the membrane bound form is responsible for signaling to the B-cell when it is crosslinked by an antigen and is required for B-cell maturation and antibody production. The two forms result from alternative splicing. Preferably, only the secreted form is modified as described herein. The membrane bound form would be completely wild type, to maintain fidelity of generation of the antibody response.
- an immune cell with the genetic modifications described herein may secrete immunoglobulin that may have possess a detectable polypeptide label fused in the heavy chain constant region, or a detectable polypeptide label fused in the light chain constant region, or the immunoglobulin may have both a heavy and light chain fusion component.
- each detectable label may be a single detectable label or a plurality of labels, in tandem or not, optionally separated from the immunoglobulin poition of the polypeptide by one or more linker sequences.
- the label on the heavy chain may be the same or different from that on the light chain, for immunoglobulins that have both heavy and light chains as fusion products.
- the fused label(s) may be at any position(s) with does not detract from the ability of the immunoglobulin to interact with and bind to its target antigen.
- the invention herein embraces any and all variations in the position, placement, linkers, and number of fused peptides or polypeptides, with the object of the invention to provide at least one detectable label on an immunglobulin molecule generated by exposure of an animal or immune cell with the aforementioned genetic modification to any immunogen capable of eliciting secretion of an antibody directed thereto.
- a mammalian organism such as a mouse, a rat, a rabbit, a goat, a cow, a donkey, a monkey, a sheep, a pig, or a horse
- Example 4 demonstrates the invention using mice, in which endogenous production of fluorescent antibodies is shown. Exposure of the animal to a preselected immunogen will elicit an antibody response, the secreted antibodies having the detectable label(s) present in every antibody molecule. For production of polyclonal antibodies, antiserum from the immunized animals may be collected, the antibodies purified if desired, for subsequent use in such areas as histochemistry, diagnostics, etc.
- detectably-labeled primary monoclonal antibodies routine methods may be. followed using an animal, such as a mouse, with the genetic makeup hereindescribed. B-cells secreting the detectably-labeled primary antibodies may be fused for immortalization, and screening and selection for stable antibody-secreting hybridomas obtained by routine methods.
- detectably-labeled primary anti-idiotype antibodies may be prepared by the foregoing methods, using antibodies as immunogen.
- the polyclonal and monoclonal antibodies generated by the methods described herein have several advantages, including 1) because the primary antibody is endogenously fluorescent, no secondary antibody or chemical labeling is required. This provides for ease of experimentation, with a wider dynamic range and avoids conjugations to the antibody that may affect affinity; 2) autofluorescent proteins are currently available in several different colors, including blue, cyan, green, yellow, and red, allowing for simultaneous labeling of several antigens, and simultaneous detection by instrumentation capable of discriminating several fluorophores simultaneously.
- a visibly-detectable and enzymatically-detectable marker provides detectability under a variety of conditions, applicable to various research and diagnostic applications, and also allows for conjugation to a therapeutic agent.
- the genetic modification(s) described herein may be achieved by a variety of procedures known in the art.
- the genetic modification is introduced by a "knock-in" procedure in which the wild-type immunoglobulin gene(s) are replaced by the detectable-label-modified genes.
- Such procedures may include the use of a bacterial artificial chromosome, as exemplified in Example 2 below, although this example is merely illustrative and non limiting as to procedures for achieving the genetically-modified mammal or mammalian cells of the invention.
- Antigens to which detectable antibodies may be raised in genetically-modified animals or immune cells as described herein are not limited to any particular types or classes of immunogen, and includes those for which a detectable antibody is desirable. Such antigens comprise a vast list. By way of non-limiting example, this includes diagnostic and research reagents for identifying the presence of and/or quantitating various medically-important biomolecules in bodily fluids, biopsy and necropsy samples, for example, all diagnostic tests which employ immunoassay protocols, including ELISA, radioimmunoassay, EMIT, immunofluorescence, fluorescence polarization, and other methods for detecting the interaction between and biomolecule of interest and an antibody thereto.
- diagnostic and research reagents for identifying the presence of and/or quantitating various medically-important biomolecules in bodily fluids, biopsy and necropsy samples, for example, all diagnostic tests which employ immunoassay protocols, including ELISA, radioimmunoassay, EMIT, immunofluorescence,
- Medical diagnostics include, by way of non- limiting example, assays for autoimmune disorders, cardiovascular disorders, diabetes, endocrine disorders, fungal, bacterial, viral, parasitic, and other infectious agents, hematologic diseases, immunologic diseases, hepatic diseases, oncologic diseases, thyroid diseases, and toxicology and drugs of use and abuse.
- assays for autoimmune disorders, cardiovascular disorders, diabetes, endocrine disorders, fungal, bacterial, viral, parasitic, and other infectious agents hematologic diseases, immunologic diseases, hepatic diseases, oncologic diseases, thyroid diseases, and toxicology and drugs of use and abuse.
- the ability to discriminate between differently labeled primary antibodies without the need for, and concomitant disintegration of signal, by multiple secondary antibodies will permit multiple analytes to be measured simultaneously, decreasing the costs and increasing the amount of information available for rendering diagnostic and therapeutic decisions.
- a genetically-modified mammal maybe prepared which responds to immunization with an antigen by the production of chimeric immunoglobulin molecules capable of reading out a signal or altering the signal produced only on binding with the target antigen.
- This signal may be, for example, an increase, decrease or change in fluorescence.
- chimeric antibodies may be used in a very simple homogeneous immunoassay in which, on combining with a sample, indicates the presence or extent of the level of the antigen in the sample. Pairs of proteins or peptides capable of undergoing such modulation in fluorescence include FRET pairs, such as described, for example, in U.S. Patent 5,998,204, incorporated herein by reference in its entirety.
- Such chimeric antibodies are prepared by following the methods described herein.
- the genes encoding the chains of the secreted immunoglobulin are modified at the polynucleotide level to provide that both a fluorescent peptide or polypeptide, and a fluorescence-quenching or -modulating peptide or polypeptide, are fused into either the heavy immunoglobulin chain or the light immunoglobulin chain in the appropriate position in the genome of the mouse.
- the positions of integration into the respective immunoglobulin components are such that the proximity of the fluorescent polypeptide and the fluorescence-quenching or -modulating polypeptide in the secreted, whole immunoglobulin molecule, change on binding of the immunoglobulin to its target antigen. This change in proximity alters the interaction between the fluorophore and the quencher or modulator resulting in a modulation in the detectable fluorescence on exposure of the immunoglobulin to its excitation wavelength.
- Such positions are selected to not alter the ability of the complete immunoglobulin molecule to assemble, be secreted, or bind the antigen. These selections are within the realm of the skilled artisan.
- Suitable fluorescent peptides or polypeptides as well as peptides and polypeptides capable of quenching or modulating the fluorescence, such as FRET pairs, are known and can be selected to provide the chimeric immunoglobulin, and mammals capable of producing the immunoglobulin after immunization.
- a rat IgG2A antibody hybridoma which produces a monoclonal antibody reactive against beta-galactosidase was used to determining whether GFP fusion proteins would be correctly assembled, secreted, and recognize antigen.
- the cDNA of the secreted form of the heavy and light chains against beta-galactosidase were cloned.
- the polynucleotide sequence encoding GFP was placed in front of the stop codon of both the heavy chain of IgG2A and light kappa chains.
- the plasmid combinations of 1) non-GFP tagged, 2) IgG2A heavy chain tagged, 3) light chain tagged, and 4) both heavy chain and light chain tagged, were transfected into 293T kidney cells and tested for ability to bind antigen.
- the 293T cells do not express any endogenous antibodies. They were transfected with two expression vectors of combinations of IgG2A and kappa chains against beta-galactosidase: 1) IgG2A and kappa; T) IgG2A and kappa-GFP; 3) IgG2A-GFP and kappa; and 4) IgG2A-GFP and kappa-GFP.
- the transfected cells will express and assemble and secrete the complete antibody. Forty-eight hours after transfection, the medium was harvested. This contained unpurified antibodies which was used for the experiments below
- Example 2 Preparation of genetically-modified (knock-in) animals comprising detectably-labeled immunoglobulin genes
- Knock-in or gene replacement involves replacing an endogenous piece of DNA in the chromosome with a constructed piece of DNA.
- the constructed DNA must correctly integrate into the same genetic location as the gene to be replaced. This is distinctly different from transgenic technology where a constructed DNA is randomly introduced into a cell.
- the VDJ variable regions of the IgGl constant chain are far upstream (5 1 ) of this area. Immediately upstream of this area are the IgM and IgD constant regions. Downstream to this area are the constant regions for IgG2a, IgG2b, IgG3, IgE, and IgA.
- the exons CHl, CH2 and Gl are spliced together to make the constant region of the secreted form.
- GFP is fused in-frame at the end of the Gl exon with a five- amino-acid linker of Gly-Gly-Ser-Gly-Gly (SEQ ID NO: 2) in-between.
- SEQ ID NO: 2 a five- amino-acid linker of Gly-Gly-Ser-Gly-Gly (SEQ ID NO: 2) in-between.
- the membrane bound form splices out the last two amino acids of Gl and thus the entire GFP. Therefore, GFP will be fused only to the secreted form.
- a bacterial artificial chromosome (BAC) containing the entire IgG region is obtained.
- the targeting vector contains the 5' homologous region directly PCRed from the BAC.
- the Gl - GFP fusion is generated by primer overlap extension PCR (Horton et al., 1990; Horton, 1995).
- a neomycin resistance gene is introduced as a selection marker. This neomycin gene is flanked on each side by a loxP site. Thus, after selection, the gene is deleted by Cre-mediated recombination. This eliminates problems due to the presence of the neomycin gene and its associated promoter (Zou et al., 1993).
- a 3' homologous region is also PCRed from the BAC.
- DTA diphtheria toxin
- embryonic stem cells are transfected with the targeting vector and selection with neomycin analog G418 is performed. Clones are screened for correct integration by Southern analysis and PCR. Subsequently, correctly targeted ES cell are injected into blastocysts and implanted into mothers. The blastocysts develop into chimeric mice, where some cells are developed from the injected ES cells. The chimeras are used to parent heterozygote mice. Two heterozygous mice are then parented to produce homozygous mice.
- mice The mouse IgGl heavy chain and kappa light chains have been previously targeted for gene replacement. In those cases, the constant chain was replaced with human constant chains and the resulting mice generated humanized antibodies (Zou et al., 1993; Zou et al., 1994).
- mice as prepared above are inoculated with the antigen of interest. After several weeks, the antibody production against the antigen is screened, as traditionally done with an ELISA, where the antigen is immobilized, the mouse serum is added, and an enzyme-linked secondary antibody against the primary is added. The presence of enzymatic activity indicates that the mouse has produced specific antibodies. Since here, the antibodies are already fluorescent, an ELISA is unnecessary and measurement of bound fluorescence is sufficient. Fusion of splenocytes from a positive mouse with myeloma cells is used to produce immortalized antibody-producing cells, following standard protocols. Further screening of colonies can be performed using simple fluorescence measurements.
- Antibody may be produced in quantity by growth of cell-hybrids, following standard protocols.
- Example 3 Homogeneous immunoassays using detectably-labeled antibodies from a genetically-modified mouse
- a genetically- modified mouse may be prepared which responds to immunization with an antigen by the production of chimeric immunoglobulin molecules capable of reading out a signal only on binding with the target antigen.
- chimeric antibodies may be used in a very simple homogeneous immunoassay in which, on combining with a sample, indicates the presence or extent of the level of the antigen in the sample.
- Such chimeric antibodies are prepared by following the methods herein. Both a fluorescent peptide or polypeptide, and a fluorescence- quenching peptide or polypeptide, are fused into either the heavy immunoglobulin chain or the light immunoglobulin chain in the appropriate position in the genome of the mouse.
- Such pairs may include FRET pairs or proteins, such as described, for example, in U.S. Patent 5,998,204, incorporated herein by reference in its entirety.
- the positions of integration into the respective immunoglobulin components are such that the proximity of the fluorescent polypeptide and the fluorescence-quenching polypeptide change on binding of the immunoglobulin to its target antigen. Such positions also do not alter the ability of the complete immunoglobulin molecule to assemble, be secreted, or bind the antigen.
- Both the fluorescent and the fluorescence-quenching protein or peptides may be fused into the same immunoglobulin component, at positions wherein antigen binding induces a conformational change and thus a proximity change among the pair and attendant modulation of fluorescence.
- Suitable pairs include a blue-shifted GFP mutant P4-3 (Y66H/Y145F) as the donor, and an improved green mutant S65T can respectively serve as a donor and an acceptor for fluorescence resonance energy transfer (FRET; Tsien et al, 1993, Trends Cell Biol. 3:242-245).
- FRET fluorescence resonance energy transfer
- a genetically-modified mouse expressing antibodies with these modifications was immunized with human chorionic gonadotropin (hCG). The fluorescence of antibodies produced by this mouse was increased upon binding to hCG.
- This reagent was used in a simplified assay in an automated fluorescence-based instrument for determining pregnancy among a large battery of other diagnostic tests on blood and urine samples.
- Example 4 Kappa-GFP knock-in mice produce fluorescent endogenous antibodies
- Kappa-GFP knock-in mice were prepared in accordance with the methods described in Example 2, above. At 8 weeks of age, animals were bled and serum was incubated with Protein A/G beads, to which antibodies in the serum bind. As shown in Figure 2, under fluorescence illumination the beads showed the characteristic fluorescence of GFP ( Figure 2A), whereas serum from wild-type mice incubated with Protein A/G beads did not ( Figure 2B). Thus, the mice produced fluorescently-labeled, endogenous immunoglobulin molecules, comprising kappa- GFP, fluorescent light chains.
- Figure 3 shows the results of PCR amplification using primers from up- and down-stream of the section of the kappa light chain where the GFP was targeted ( Figure 3A), or using GFP primers ( Figure 3B), from DNA extracts from a number of mice prepared in accordance with the present invention.
- the segment amplified from wild type kappa light chains is the smallest and runs the fastest on the gel (as indicated).
- the segment amplified with the GFP insert is larger and migrates slower.
- lane 2 has only the faster moving product and is therefore from a mouse that is homozygous for wild-type kappa light chain.
- Lanes 3, 5, and 7-12 have both products, which indicates that the mice are heterozygous.
- Lanes 1, 4, and 6 only have the slower moving product indicating that they are homozygous for the kappa with the inserted GFP.
- Figure 3B shows using primers from the GFP coding region that lane 2 was negative for GFP, consistent with the observation that this mouse did not produce a PCR product from kappa- GFP. Lanes 1 and 2-12 were positive for GFP, consistent with the results from the top panel.
- Cre-loxP-mediated gene replacement a mouse strain producing humanized antibodies. Curr. Biol. 4, 1099-1103.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Genetically-modified non-human mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.
Description
ANIMALS, CELLS AND METHODS FOR PRODUCTION OF DETECTABLY-LABELED ANTIBODIES
FIELD OF THE INVENTION
[0001] The invention is directed to methods for obtaining detectably-labeled antibodies to any antigen by using genetically-modified mammals which express at least one detectably-labeled antibody molecule component.
BACKGROUND OF THE INVENTION
[0002] Antibodies are widely used for diagnostic and research purposes for localizing an antigen within a cell, tissue, or other biological sample. For histopathology or cytology, cells are usually first exposed to a primary antibody which is specific for the desired target antigen but not directly detectable. In a subsequent step, the primary antibody is detected with a labeled secondary antibody which recognizes the primary antibody. This procedure is somewhat cumbersome and may result in undesirable background staining due to non-specific reactivity of the secondary antibody. As a result of the divalent primary reacting with the protein, and then a divalent secondary reacting with the primary, the relationship between the protein and the detectable signal is extremely non-linear, with a limited dynamic range between the minimal detectable signal and saturation. In addition, in order to visualize two or more antigens, the primary antibodies must be from two different species such that each secondary antibody is not cross- reactive; expensive species-specific secondary antibodies must therefore be used for each primary antibody. With advances in optical and digital imaging and detection, multiply-labeled samples and simultaneous detection of several analytes is possible, yet the aforementioned biological limitations do not permit full advantage to be taken of these advances. Moreover, since monoclonal antibodies are generated typically only in mice and rats, in conventional dual or triple labeling, only one antibody can be monoclonal. This is often a limiting important restriction.
[0003] Several techniques are available to circumvent these limitations, including direct chemical conjugation of the primary antibody with a detectable molecule, or direct conjugation with biotin and subsequence detection with a fluorescent avidin. These procedures are
cumbersome, require purification of the primary antibodies, and the conjugation procedure almost always affects the affinity of the antibody for its target.
[0004] It is towards the facile preparation of a detectable primary antibody to any desired antigen that the present invention is directed.
[0005] The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application.
SUMMARY OF THE INVENTION
[0006] In its broadest aspect, the invention is directed to a genetically-modified non-human mammal capable of expressing at least one chimeric immunoglobulin gene comprising at least one detectable protein or peptide fused with a gene expressing an immunoglobulin component. The immunoglobulin component may be selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof. The antibodies secreted by the immune cells of the genetically-modified mammal comprise said at least one detectable protein or peptide. The immunoglobulin heavy chain gene may be IgG, IgM, IgD or IgA. The immunoglobulin component may be a complete immunoglobulin molecule comprising two heavy and two light chains. In one embodiment, the at least one detectable peptide or protein is present at the C- terminus of the gene product of the fusion polynucleotide; preferably, the at least one detectable peptide or protein present at the C-terminus of the gene product of the fusion polynucleotide is located in exon Gl. In another embodiment, the at least one detectable peptide or protein is present at the C-terminus of the gene product of the fusion polynucleotide with a flexible linker peptide located between the detectable peptide or protein and the immunoglobulin component. Preferably, the at least one detectable peptide or protein present at the C-terminus of the gene product of said fusion polynucleotide with a flexible linker located between the detectable peptide or protein and the immunoglobulin component is located in exon Gl .
[0007] In one particular embodiment, the invention provides a genetically-modified non-human mammal containing a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group
consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least one detectable protein, wherein said non-human mammal is capable of expressing at least one detectable protein fused with said immunoglobulin component wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises said at least one detectable protein.
[0008] In another particular embodiment, the invention is directed to a genetically-modified non- human mammal containing a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin molecule comprising two heavy chains and two light chains, and a nucleic acid encoding at least one detectable protein, wherein said non-human mammal is capable of expressing said at least one detectable protein fused with said immunoglobulin molecule wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises said at least one detectable protein.
[0009] In another particular embodiment, the invention is directed to a genetically-modified non- human mammal containing a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least two detectable proteins, wherein said non-human mammal is capable of expressing at least two detectable proteins fused with said immunoglobulin component wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises said at least two detectable proteins.
[0010] In another particular embodiment, the invention is directed to a genetically-modified non- human mammal containing a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin molecule comprising two heavy chains and two light chains, and a nucleic acid encoding at least two detectable proteins, wherein said non-human mammal is capable of expressing at least two detectable proteins fused with said immunoglobulin molecule wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises said at least two detectable proteins.
[0011] In another particular embodiment, the genetically-modified non-human mammal is a non- domestic animal selected from a rodent, a rabbit, a goat, a pig, a horse, a cow, a donkey, a monkey and a sheep. In a more particular embodiment, the non-human mammal is a mouse or a rat. In another embodiment, the non-human mammal may be selected from a domestic mammal such as, but not limited to, a dog or cat.
[0012] In another particular embodiment, the immunoglobulin molecule secreted by immune cells of the above-mentioned genetically-modified mammal comprises at least one detectable protein or peptide in the heavy chain of the immunoglobulin molecule. In another embodiment, the immunoglobulin molecule secreted by immune cells of the genetically-modified mammal comprises at least one detectable protein or peptide in the light chain of said immunoglobulin molecule. In a further embodiment, the immunoglobulin molecule secreted by immune cells of the genetically-modified mammal comprises at least one detectable protein or peptide in the heavy chain and at least one detectable protein or peptide in the light chain of said immunoglobulin molecule. In another particular embodiment, the at least one detectable label may be found in both of the light chains and/or in both of the heavy chains of the immunoglobulin molecule.
[0013] In another particular embodiment, the immunoglobulin molecule secreted by immune cells of the above-mentioned genetically-modified mammal comprises at least two detectable proteins or peptides in the heavy chain of the immunoglobulin molecule. In another embodiment, the immunoglobulin molecule secreted by immune cells of the genetically-modified mammal comprises at least two detectable proteins or peptides in the light chain of said immunoglobulin molecule. In a further embodiment, the immunoglobulin molecule secreted by immune cells of the genetically-modified mammal comprises at least two detectable proteins or peptides in the heavy chain and at least two detectable proteins or peptides in the light chain of said immunoglobulin molecule. In another particular embodiment, the at least two detectable labels may be found in both of the light chains and in both of the heavy chains of the immunoglobulin molecule.
[0014] In another embodiment of the invention, at least one of the aforementioned detectable proteins or polypeptides is an autofluorescent protein or peptide, a visibly-detectable protein or peptide, an enzymatically active protein or peptide, a protein or peptide capable of interacting with another molecule to produce a detectable product, or any combination thereof. In yet another particular embodiment, the protein capable of interacting with another molecule to produce a detectable product is selected from, but not limited to, the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation or a chitin-binding domain, or any combination thereof. The protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of the detectable product, or to add an additional fluorophore or to add a therapeutic molecule. In another embodiment, the detectable protein or polypeptide is capable of quenching or modulating fluorescence. Non-limiting examples of autofluorescent proteins or peptides include green fluorescent protein, red fluorescent protein, a fluorescent analog, or fragment of any of the foregoing, or a luminescent protein. In another embodiment, the at least one detectable protein is a combination of an autofluorescent protein or peptide and an enzymatically-active protein or peptide, such as but not limited to a combination of green fluorescent protein and alkaline phosphatase.
[0015] In another broad aspect of the invention, a genetically-modified immune cell is provided which is capable of expressing at least one chimeric immunoglobulin gene comprising at least one detectable protein or peptide fused with a gene expressing an immunoglobulin component. The immunoglobulin component may be selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof. Antibodies secreted by the genetically-modified immune cell comprise the at least one detectable protein or peptide. The immunoglobulin heavy chain gene may be IgG, IgM, IgD or IgA. The immunoglobulin component may be a complete immunoglobulin molecule comprising two heavy and two light chains. In one non-limiting example, the at least one detectable peptide or protein is present at the C-terminus of the gene product of the fusion polynucleotide; preferably, the polynucleotide encoding the at least one detectable peptide or protein present at the C-terminus of the gene product of said fusion polynucleotide is located in exon Gl. hi another embodiment, the at least one detectable peptide or protein present at the C-terminus of the gene product of said fusion polynucleotide has a
flexible linker peptide between the detectable peptide or protein and the immunoglobulin component; preferably, the polynucleotide encoding the at least one detectable peptide or protein present at the C-terminus of the gene product of said fusion polynucleotide with a flexible linker therebetween is located in exon Gl .
[0016] In a more particular embodiment, the invention provides a genetically-modified immune cell having a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, a nucleic acid encoding at least one detectable protein, and a nucleic acid encoding a flexible linker peptide located between the nucleic acid encoding the immunoglobulin component and the nucleic acid encoding the at least one detectable protein, and wherein said immune cell is capable of expressing at least one detectable protein fused with said immunoglobulin molecule, with the flexible linker peptide between the immunoglobulin molecule and the at least one detectable protein, wherein antibodies secreted by said genetically- modified immune cell comprise said at least one detectable protein.
[0017] In another more particular embodiment, the invention provides a genetically-modified immune cell having a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin molecule comprising two heavy and two light chains, a nucleic acid encoding at least one detectable protein, and a nucleic acid encoding a flexible linker peptide located between the nucleic acid encoding the immunoglobulin molecule comprising two heavy and two light chains and the nucleic acid encoding the at least one detectable protein, and wherein said immune cell is capable of expressing at least one detectable protein fused with said immunoglobulin molecule, with the flexible linker peptide between the immunoglobulin molecule and the at least one detectable protein, wherein antibodies secreted by said genetically-modified immune cell comprise said at least one detectable protein.
[0018] In yet another more particular embodiment, the invention provides a genetically-modified immune cell having a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an
immunoglobulin heavy chain, and any combination thereof, a nucleic acid encoding at least two detectable proteins, and a nucleic acid encoding a flexible linker peptide located between the nucleic acid encoding the immunoglobulin component and the nucleic acid encoding the at least two detectable proteins, and wherein said immune cell is capable of expressing at least two detectable proteins fused with said immunoglobulin component, with the flexible linker peptide between the immunoglobulin component and the at least two detectable proteins, wherein antibodies secreted by said genetically-modified immune cell comprise said at least two detectable proteins.
[0019] In yet another more particular embodiment, the invention provides a genetically-modified immune cell having a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin molecule comprising two heavy and two light chains, a nucleic acid encoding at least two detectable proteins, and a nucleic acid encoding a flexible linker peptide located between the nucleic acid encoding the immunoglobulin molecule and the nucleic acid encoding the at least two detectable proteins, and wherein said immune cell is capable of expressing at least two detectable proteins fused with said immunoglobulin molecule, with the flexible linker peptide between the immunoglobulin molecule and the at least two detectable proteins, wherein antibodies secreted by said genetically-modified immune cell comprise said at least two detectable proteins.
[0020] In another particular embodiment, the immunoglobulin molecule secreted by the aforementioned immune cell may comprise at least one detectable protein or peptide in the heavy chain of the immunoglobulin molecule, or it may comprise at least one detectable protein or peptide in the light chain of said immunoglobulin molecule. In another embodiment, the immunoglobulin molecule secreted by the genetically-modified immune cells described above comprises at least one detectable protein or peptide in the heavy chain and at least one detectable protein or peptide in the light chain of the immunoglobulin molecule. In another particular embodiment, the at least one detectable label may be found in one or in both of the light chains and in one or in both of the heavy chains of the immunoglobulin molecule or any combination thereof. In a further embodiment, the immunoglobulin molecule secreted by immune cells of the genetically-modified mammal comprises at least two detectable proteins or peptides in one or
both of the heavy chains and at least two detectable proteins or peptides in one or both of the light chains of said immunoglobulin molecule.
[0021] The aforementioned genetically-modified immune cell may have at least one detectable protein or polypeptide that is capable of quenching or modulating fluorescence; or the protein or peptide is an autofluorescent protein or peptide, a visibly-detectable protein or peptide, an enzymatically active protein or peptide, a protein or peptide capable of interacting with another molecule to produce a detectable product, or any combination thereof. In yet another particular embodiment, the protein capable of interacting with another molecule to produce a detectable product is selected from the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, or a chitin-binding domain, a consensus sequence for biotinylation, or any combination thereof. The protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of the detectable product. In the example wherein the at least one detectable protein is an autofluorescent protein or peptide, it may be, by way of non-limiting example, green fluorescent protein, red fluorescent protein, or a fluorescent analog or fragment of any of the foregoing. In another embodiment, the at least one detectable protein is a combination of an autofluorescent protein or peptide and an enzymatically-active protein or peptide, such as but not limited to a combination of green fluorescent protein and alkaline phosphatase.
[0022] In another particular embodiment, the at least one or at least two detectable proteins are present at the C-terminus of the gene product of the fusion polynucleotide in the genetically- modified immune cell. In another particular embodiment, the nucleic acid encoding the at least one or at least two detectable proteins present at the C-terminus of the gene product of the fusion polynucleotide is located in exon Gl.
[0023] In yet another particular embodiment, the antibody secreted by the immune cell comprises at least two detectable proteins in the heavy chain of said antibody. In yet another particular embodiment, the antibody secreted by the genetically-modified immune cell comprises at least two detectable proteins in the light chain of said antibody. In yet another particular embodiment, the antibody secreted by the genetically-modified immune cell comprises at least two detectable proteins in the heavy chain and at least two detectable proteins in the light chain of the antibody.
In yet another particular embodiment, the immunoglobulin heavy chain is selected from the group consisting of IgG, IgM, IgD and IgA.
[0024] The invention is also directed to a hybridoma generated from any of the genetically- modified immune cells as mentioned above.
[0025] In yet another aspect, the invention is directed to a chimeric, detectably-labeled immunoglobulin molecule comprising at least one detectable protein or peptide fused with an immunoglobulin component. The immunoglobulin component may be selected from the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, or any combination thereof. The immunoglobulin component may be a complete immunoglobulin molecule comprising two heavy chains and two light chains. The at least one detectable peptide or protein maybe present at the C-terminus of the gene product of said fusion polynucleotide, preferably located in exon Gl . A flexible linker peptide may be provided therebetween. In another embodiment, a polynucleotide encoding said at least one detectable peptide or protein present at the C-terminus of the gene product of said fusion polynucleotide with a flexible linker therebetween is located in exon Gl. The chimeric, detectably-labeled immunoglobulin molecule may have an immunoglobulin heavy chain gene is selected from IgG, IgM, IgD and IgA. At least one detectable protein or peptide may be present in the heavy chain of said immunoglobulin molecule, the at least one detectable protein or peptide may be present in the light chain of said immunoglobulin molecule, or, in a further embodiment, the at least one detectable protein or peptide may be present in the heavy chain and at least one detectable protein or peptide in the light chain of said immunoglobulin molecule. In another particular embodiment, the at least one detectable label may be found in both of the light chains and in both of the heavy chains of the immunoglobulin molecule.
[0026] The aforementioned chimeric, detectably-labeled immunoglobulin molecule may have at least one detectable protein or polypeptide that is capable of quenching or modulating fluorescence; or, the at least one detectable protein or peptide is an autofiuorescent protein or peptide, a visibly-detectable protein or peptide, an enzymatically active protein or peptide, a protein or peptide capable of interacting with another molecule to produce a detectable product, or any combination thereof. In yet another particular embodiment, the protein capable of
interacting with another molecule to produce a detectable product is selected from the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation, or a chitin-binding domain, or any combination thereof. The protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of the detectable product. In one embodiment, the at least one detectable protein is an autofluorescent protein or peptide, such as but not limited to green fluorescent protein, red fluorescent protein, or a fluorescent analog or fragment of any of the foregoing. In another embodiment, the at least one detectable protein may be a combination of an autofluorescent protein or peptide and an enzymatically-active protein or peptide, such as but not limited to a combination of green fluorescent protein and alkaline phosphatase.
[0027] In another more particular aspect, the invention provides a genetically-modified non- human mammal whose genome comprises a fusion polynucleotide, wherein the fusion polynucleotide comprises a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least one detectable protein, wherein the non-human mammal is capable of expressing the at least one detectable protein fused with the immunoglobulin component and wherein an antibody secreted by an immune cell of the genetically-modified non-human mammal comprises the at least one detectable protein.
[0028] In yet another more particular aspect, the invention provides a genetically-modified non- human mammal whose genome comprises a fusion polynucleotide, wherein the fusion polynucleotide comprises a nucleic acid encoding an immunoglobulin molecule comprising two heavy and two light chains, and a nucleic acid encoding at least one detectable protein, wherein the non-human mammal is capable of expressing the at least one detectable protein fused with the immunoglobulin molecule and wherein an antibody secreted by an immune cell of the genetically-modified non-human mammal comprises the at least one detectable protein.
[0029] In yet another more particular aspect, the invention provides a genetically-modified non- human mammal whose genome comprises a fusion polynucleotide, wherein the fusion polynucleotide comprises a nucleic acid encoding an immunoglobulin component selected from
the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least two detectable proteins, wherein the non-human mammal is capable of expressing the at least two detectable proteins fused with the immunoglobulin component and wherein an antibody secreted by an immune cell of the genetically-modified non-human mammal comprises the at least two detectable proteins.
[0030] In yet another more particular aspect, the invention provides a genetically-modified non- human mammal whose genome comprises a fusion polynucleotide, wherein the fusion polynucleotide comprises a nucleic acid encoding an immunoglobulin molecule comprising two heavy and two light chains, and a nucleic acid encoding at least two detectable proteins, wherein the non-human mammal is capable of expressing the at least two detectable proteins fused with the immunoglobulin molecule and wherein an antibody secreted by an immune cell of the genetically-modified non-human mammal comprises the at least two detectable proteins.
[0031] In another embodiment, the at least one or at least two detectable labels may be present in one or both of the heavy and light chains.
[0032] In one embodiment, the genetically-modified non-human mammal is a non-domestic animal selected from a rodent, a rabbit, a goat, a pig, a horse, a cow, a donkey, a monkey and a sheep. In a particular embodiment, the non-human mammal is a mouse. In a more particular embodiment, the non-human mammal is a mouse or rat. In another embodiment, the non-human mammal may be selected from a domestic mammal such as, but not limited to, a dog or cat.
[0033] In another embodiment, the at least two detectable proteins encoded by the fusion polynucleotide are present at the C-terminus of the gene product of the fusion polynucleotide. In another particular embodiment, the nucleic acid encoding the at least two detectable proteins present at the C-terminus of the gene product of the fusion polynucleotide is located in exon Gl . In another particular embodiment, the at least two detectable proteins are present at the C- terminus of the gene product of the fusion polynucleotide with a flexible linker peptide located between the at least two detectable proteins and the immunoglobulin component.
[0034] In yet another particular embodiment, the antibody secreted by an immune cell of the genetically-modified mouse comprises at least two detectable proteins in the heavy chain of the antibody. In yet another particular embodiment, the antibody secreted by an immune cell of the genetically-modified mouse comprises at least two detectable proteins in the light chain of the antibody. In yet another particular embodiment, the antibody secreted by an immune cell of the genetically-modified mouse comprises at least two detectable proteins in the heavy chain and at least two detectable proteins in the light chain of the antibody. In yet another particular embodiment, the immunoglobulin heavy chain is selected from the group consisting of IgG, IgM, IgD and IgA.
[0035] In yet another particular embodiment, the at least one of the at least two detectable proteins is capable of quenching fluorescence. In yet another particular embodiment, at least one of the at least two detectable proteins is an auto fluorescent protein, a visibly-detectable protein, an enzymatically active protein, or a protein capable of interacting with another molecule to produce a detectable product, or any combination thereof. In yet another particular embodiment, the protein capable of interacting with another molecule to produce a detectable product is selected from the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation or a chitin-binding domain, or any combination thereof. The protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of the detectable product, or to add an additional fluorophore or to add a therapeutic molecule.
[0036] In yet another particular embodiment, the at least one of the at least two detectable proteins is an autofluorescent protein. In yet another particular embodiment, non-limiting examples of autofluorescent proteins or peptides include green fluorescent protein, cyan fluorescent protein, yellow fluorescent protein, red fluorescent protein, and a fluorescent analog or fragment of any of the foregoing. In yet another particular embodiment, the autofluorescent protein is green fluorescent protein. In yet another particular embodiment, the at least one detectable protein is a combination of an autofluorescent protein and an enzymatically-active protein. In yet another particular embodiment, the at least one detectable protein is a combination of green fluorescent protein and alkaline phosphatase.
[0037] In another more particular aspect, the invention provides a genetically-modified non- human mammal capable of producing a detectably-labeled antibody in response to immunization by an antigen, the genome of said non-human mammal comprising a fusion polynucleotide comprising a nucleic acid encoding at least one detectable protein and a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, wherein an antibody secreted by an immune cell of said genetically- modified non-human mammal comprises one detectable protein.
[0038] In another more particular aspect, the invention provides a genetically-modified non- human mammal capable of producing a detectably-labeled antibody in response to immunization by an antigen, the genome of said non-human mammal comprising a fusion polynucleotide comprising a nucleic acid encoding at least one detectable protein and a nucleic acid encoding an immunoglobulin molecule comprising two heavy chains and two light chains, wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises one detectable protein.
[0039] In a further aspect, the invention is also directed to a genetically-modified mammal capable of producing a detectably-labeled immunoglobulin in response to immunization by an antigen, the genome of the mammal comprising at least one fusion polynucleotide consisting of a polynucleotide sequence encoding at least two detectable proteins or peptides fused with a the kappa immunoglobulin light chain gene, the lambda immunoglobulin light chain gene, an immunoglobulin heavy chain gene, or any combination thereof, wherein antibodies secreted by immune cells of the genetically-modified mammal comprise the at least two detectable proteins or peptides. In one particular embodiment, the genetically-modified mammal is a mouse, although other genetically-modified mammals may be selected from a goat, a pig, a horse, a cow, a dog, a cat, a donkey, a monkey and a rabbit, and other rodents, including rats, and any other domestic or non-domestic animal.
[0040] In a yet further aspect, the invention is also directed to a genetically-modified mammal capable of producing a detectably-labeled immunoglobulin in response to immunization by an antigen, the genome of the mammal comprising at least one fusion polynucleotide consisting of a
polynucleotide sequence encoding at least two detectable proteins or peptides fused with an immunoglobulin molecule comprising two heavy and two light chains, wherein antibodies secreted by immune cells of the genetically-modified mammal comprise the at least two detectable proteins or peptides. In one particular embodiment, the genetically-modified mammal is a mouse, although other genetically-modified mammals may be selected from a goat, a donkey, a monkey, a pig, a horse, a cow, a dog, a cat, a rabbit, and other rodents, including rats, and any other domestic or non-domestic animal.
[0041] In another more particular aspect, the invention provides a hybridoma capable of producing an antibody having at least two detectable proteins as described herein.
[0042] In a further aspect, the invention is directed to a chimeric, detectably-labeled immunoglobulin molecule comprising at least one fluorescent protein or peptide and at least one fluorescence-quenching or -modulating protein or peptide fused with a component of the immunoglobulin molecule independently selected from either the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, or any combination thereof.
[0043] In another more particular aspect, the invention provides a chimeric, detectably-labeled immunoglobulin molecule comprising at least two detectable proteins or peptides fused with the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, or any combination thereof.
[0044] In one particular embodiment, the chimeric, detectably-labeled immunoglobulin molecule is encoded by a fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least two detectable peptides or proteins that are present at the C-terminus of the gene product of the fusion polynucleotide. In yet another particular embodiment, the nucleic acid encoding the at least two detectable peptides or proteins present at the C terminus of the gene product of the fusion polynucleotide is located in exon Gl . In another particular embodiment, the at least two detectable peptides or proteins that are present at the C-
terminus of the gene product of a fusion polynucleotide contain a flexible linker peptide located between the at least two detectable proteins and the immunoglobulin component. In yet another particular embodiment, the immunoglobulin heavy chain is selected from the group consisting of IgG, IgM, IgD and IgA.
[0045] In yet another particular embodiment, the chimeric, detectably-labeled immunoglobulin may have at least two detectable proteins or peptides in the heavy chain of the immunoglobulin molecule. In yet another particular embodiment, the chimeric, detectably-labeled immunoglobulin may have at least two detectable proteins or peptides in the light chain of the immunoglobulin molecule, hi yet another particular embodiment, the chimeric, detectably- labeled immunoglobulin may have at least two detectable proteins or peptides in the heavy chain and at least two detectable proteins or peptides in the light chain of the immunoglobulin molecule.
[0046] In yet another particular embodiment, the aforementioned chimeric, detectably-labeled immunoglobulin molecule may have one of the at least two detectable proteins or peptides that is capable of quenching fluorescence. In yet another particular embodiment, the chimeric, detectably-labeled immunoglobulin molecule may have at least one of the at least two detectable proteins or peptides that is an autofluorescent protein or peptide, a visibly-detectable protein or peptide, an enzymatically active protein or peptide, or a protein or peptide capable of interacting with another molecule to produce a detectable product, or an analog or fragment thereof. In yet another particular embodiment, the protein capable of interacting with another molecule to produce a detectable product is selected from the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation, or a chitin- binding domain, or any combination thereof. The protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of the detectable product, or to add an additional fluorophore or to add a therapeutic molecule. In yet another particular embodiment, the chimeric, detectably-labeled immunoglobulin molecule may have at least one of the at least two detectable proteins that is an autofluorescent protein or peptide. In yet another particular embodiment, the chimeric, detectably-labeled immunoglobulin molecule may have at least one of the at least two autofluorescent proteins or peptides selected from the group consisting of green fluorescent protein, red fluorescent protein, and a fluorescent
analog or fragment of any of the foregoing. In yet another particular embodiment, the autofluorescent protein may be green fluorescent protein. In yet another particular embodiment, the at least one of the at least two detectable proteins may be a combination of an autofluorescent protein or peptide and an enzymatically-active protein or peptide. In yet another particular embodiment, the at least one of the two detectable proteins maybe a combination of green fluorescent protein and alkaline phosphatase.
[0047] In a further aspect, the present invention provides a method for producing a quantity of detectably-labelled polyclonal antibodies by carrying out at least the steps of a) providing a genetically-modified mammal as described hereinabove; b) immunizing the genetically-modified mammal with a preselected immunogen, wherein the genetically-modified mammal generates antibodies to the immunogen, wherein antibodies secreted by immune cells of the genetically- modified mammal comprise the at least one detectable protein or peptide; and c) isolating the detectably-labelled antibodies from the genetically-modified mammal.
[0048] The invention is also directed to a method for producing a quantity of detectably-labelled monoclonal antibodies comprising the steps of a) preparing a genetically-modified mammal in accordance with the above description; b) immunizing the genetically-modified mammal with a preselected immunogen, wherein immune cells of the genetically-modified mammal generate antibodies to the immunogen, wherein antibodies secreted by the immune cells comprise the at least one detectable protein or peptide; c) immortalizing antibody-producing immune cells isolated from the genetically- modified mammal; d) selecting immortalized immune cells isolated from the genetically-modified mammal that secrete antibodies specific to the immunogen; and e) preparing a quantity of detectably-labeled monoclonal antibodies from the selected immune cells.
[0049] These and other aspects of the present invention will be better appreciated by reference to the following drawings and Detailed Description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 shows the beta-galactosidase-binding activity of a chimeric fusion immunoglobulin secreted from 293T cells transfected with nucleic' acid encoding a green- fluorescent-protein-labeled heavy immunoglobulin (IgG2) chain and a green-fluorescent-protein- labeled light (kappa) chain hybrid anti-beta-galactosidase immunoglobulin.
[0051] Figures 2 A-B show the fluorescence of antibodies in serum from kappa-GFP knock-in mice bound to Protein A/G beads, as compared to those from wild-type mice.
[0052] Figure 3 A-B demonstrate using PCR amplification that mice of the invention may be homozygous or heterozygous for the kappa-GFP gene, using kappa light chain primers (Figure 3A). Use of GFP primers (Figure 3B) confirm the presence or absence of the GFP insert.
DETAILED DESCRIPTION OF THE INVENTION
[0053] The inventors herein have discovered a novel and facile method for preparing useful quantities of detectably-labeled polyclonal or monoclonal antibodies to any preselected immunogen. The method spares the need to perform any modification of the immunogen- specific (primary) antibody to provide a detectable label thereon, such as conjugation to a fluorophore or enzyme, as the detectably-labeled antibodies of the invention are inherently labeled as they are expressed and secreted from genetically-modified immune system cells. In its broadest aspect, the invention provides genetically-modified animals and immune cells from such animals in which the constant region of the heavy and/or the light chain components of the antibodies produced by the animals or cells is fused with a detectable polypeptide, such as a fluorescent polypeptide, these fusion protein(s) resulting from the expression of a genetic modification of the heavy and/or light chain genes wherein the polynucleotide encoding the detectable label is incorporated into the respective genes. Such genetically-modified animals or cells are provided such that any antibody expressed and secreted by the animal or cell comprises at least one labeled constant region. Thus, the mere induction of a humoral immune response generates the desired detectably-labeled antibody.
[0054] The detectable labels of the invention may be polypeptides, such as proteins or peptides, and they may be introduced into the genome of a mammalian organism by such methods as homologous recombination and transfection, but such methods are not intended to be limiting whatsoever, and one of skill in the art may prepare the construct(s) and modified cells in any appropriate manner. Embryonic stem cells may be so modified such that the genome of the animal resulting therefrom comprises the genetic modification. Several examples provided below are for illustrative purposes only.
[0055] The term "detectable" refers to anything that allows the presence of the antibody to be detected. Any such molecule that allows the detection of the antibody should have no effect on the ability of the animal to generate a full spectrum antibody response. Any such molecule that allows for the detection of the antibody should have no effect on the synthesis and assembly of the four molecules that form the complete antibody (the two heavy and two light chains). Any such molecule that allows for the detection of the antibody should have no effect on the transport of the assembled antibody out of the cell. Any such molecule that allows for the detection of the antibody should have no effect on the affinity of the antibody for its target. The detectable polypeptide may be, by way of non-limiting example, a fluorescent polypeptide, a luminescent polypeptide, a visibly-colored polypeptide, a polypeptide with enzymatic activity, or a polypeptide capable of interacting with or binding to another molecule to produce a detectable product. In one particular embodiment, the label is one that requires no direct interaction or further sample processing for detectability, and thus is detectable by the application of exogenous methods such as absorbance of light, fluorescence, etc. In a more particular embodiment, the label is a fluorescent polypeptide. In another more particular embodiment, the label is green fluorescent protein and its polypeptide relatives.
[0056] Moreover, a plurality of detectable labels may be present in the antibodies produced by the animals or cells of the invention. For example, both a fluorescent label and an enzyme label may be appended in tandem to the C-terminus of an immunoglobulin heavy chain gene, such that the resulting expressed and assembled immunoglobulin molecule is detectable both by fluorescence and by histochemistry, by use of a fluorigenic and chromogenic/precipitating substrate of the enzyme, respectively. In another example, the antibody is detectable
fluorometrically and by Western blot. In another example the antibody is detectable fluorometrically and a conjugation tag is used to add a therapeutic agent. As noted above, either or both the heavy and light chain constant regions may be independently modified as described herein, both with the same single or plurality of labels, or, for example, the heavy chain with a fluorescent label and the light chain with an enzyme label. These particular examples of multiple labels on multiple sites of the antibodies are merely illustrative of the range of directly-labeled antibodies that the skilled artisan may be directed to prepare following the teachings herein, and any particular example or embodiment is not intended to be limiting whatsoever.
[0057] Examples of fluorescent polypeptides include but are not limited to green fluorescent protein and other related polypeptide fluorophores which may produce other colors; the availably of individually-detectable primary antibodies in a mixture allows for the simultaneous localization or quantitation of multiple target antigens or analytes in a biological sample. One particular embodiment of the invention utilizes the green fluorescent protein of Aequorea victoria. A cDNA for the protein has been cloned (D. C. Prasher et al., "Primary structure of the Aequorea victoria green-fluorescent protein," Gene (1992) 111:229-33.). Aequorea green fluorescent protein ("GFP") is a stable, proteolysis-resistant single chain of 238 residues and has two absorption maxima at around 395 and 475 nm; Excitation at the primary absorption peak of 395 nm yields an emission maximum at 508 nm with a quantum yield of 0.72-0.85 (O. Shimomura and F. H. Johnson J. Cell. Comp. Physiol. 59:223 (1962); J. G. Morin and J. W. Hastings, J. Cell. Physiol. 77:313 (1971); H. Morise et al. Biochemistry 13:2656 (1974); W. W. Ward Photochem. Photobiol. Reviews (Smith, K. C. ed.) 4:1 (1979); A. B. Cubitt et al. Trends Biochem. Sci. 20:448-455 (1995); D. C. Prasher Trends Genet. 11:320-323 (1995); M. Chalfie Photochem. Photobiol. 62:651-656 (1995); W. W. Ward. Bioluminescence and Chemiluminescence (M. A. DeLuca and W. D. McElroy, eds) Academic Press pp. 235-242 (1981); W. W. Ward & S. H. Bokman Biochemistry 21 :4535-4540 (1982); W. W. Ward et al. Photochem. Photobiol. 35:803-808 (1982)). Mutants of GFP are embraced herein as they provide certain other characteristics, such as mutation of Serine 65 to Thr (S65T) simplifies the excitation spectrum to a single peak at 488 nm of enhanced amplitude (R. Heim et al. Nature 373:664-665 (1995)), which no longer gives signs of conformational isomers (A. B. Cubitt et al. Trends Biochem. Sci. 20:448-455 (1995)). In another example, U.S. Patent No. 6,077,707 describes a nucleic acid molecule comprising a nucleotide sequence encoding a functional
engineered fluorescent protein whose amino acid sequence is substantially identical to the amino acid sequence of Aequorea green fluorescent protein but differs by at least a substitution at T203 and, in particular, T203X, wherein X is an aromatic amino acid selected from H, Y, W or F. In one embodiment therein, the amino acid sequence further comprises a substitution at S65, wherein the substitution is selected from S65G, S65T, S65A, S65L, S65C, S65V and S65I. In another embodiment, the amino acid sequence differs by no more than the substitutions S65T/T203H; S65T/T203Y; S72A/F64L/S65G/T203Y; S65G/V68L/Q69K/S72A/T203Y; S72A/S65G/V68L/T203Y; S65G/S72A/T203Y; or S65G/S72A/T203W. In another embodiment, the nucleotide sequence encoding the protein differs from the nucleotide sequence of native green fluorescent protein by the substitution of at least one codon encoding an amino acid substitution at L42, V61, T62, V68, Q69, Q94, N121, Y145, H148, V150, F165, 1167, Ql 83, Nl 85, L220, E222 (not E222G), or V224. In another embodiment, the amino acid substitution is: L42X, wherein X is selected from C, F, H, W and Y, V61 X, wherein X is selected from F, Y, H and C, T62X, wherein X is selected from A, V, F, S, D, N, Q, Y, H and C, V68X, wherein X is selected from F, Y and H, Q69X, wherein X is selected from K, R, E and G, Q94X, wherein X is selected from D, E, H, K and N, N121X, wherein X is selected from F, H, W and Y, Y145X, wherein X is selected from W, C, F, L, E, H, K and Q, H148X, wherein X is selected from F, Y, N, K, Q and R, Vl 5OX, wherein X is selected from F, Y and H, F165X, wherein X is selected from H, Q, W and Y, I167X, wherein X is selected from F, Y and H, Q183X, wherein X is selected from H, Y, E and K, N185X, wherein X is selected from D, E, H, K and Q, L220X, wherein X is selected from H, N, Q and T, E222X, wherein X is selected from N and Q, or V224X, wherein X is selected from H, N, Q, T, F, W and Y. These examples are merely illustrative of the wide selection of fluorescent polypeptides and their corresponding polynucleotide sequences that may be employed in the preparation of the genetically-modified cells or animals of the invention.
[0058] Another example of a fluorescent protein is red fluorescent protein from coral (Matz et. al, 1999, Nature Biotechnology 17:969). Fluorescent peptides or fluorescent protein fragments of these and other fluorescent proteins are also embraced herein. In another example of a detectable polypeptide, polypeptide labels capable of being detected include those containing four cysteines at the i, i+1, i+4, and i+5 positions (i.e., WEAAAREACCRECCARA (SEQ ID NO: I)). These peptides will bind specifically to the fluorescein derivative 4',5'-bis(l,3,2-
dithioarsolan-2-yl)fluorescein (FLASH), which is non-fluorescent until bound. The use of such peptides has the advantage of providing fusion proteins of much smaller size than GFP, and fluorescence is easily detected by addition of FLASH (Griffin et. al., 1998, Science 281:269). Thus, the use of polypeptides that are capable of specifically binding a detectable label are embraced herein as another embodiment of the present invention.
[0059] Examples of polypeptides capable of being detected by enzymatic activity include various enzymes and catalytic polypeptide fragments thereof. Particularly preferred enzymatic labels include those which are able to produce a detectable color or fluorophore in a single step requiring a minimum or reagents, such as alkaline phosphatase, which can cleave a chromogenic substrate, such as p-nitrophenyl phosphate, or a fluorigenic substrate, such as ECF substrate (Amersham/Pharmacia); and a fluorigenic horseradish peroxidase substrate, FluoroBlot (Pierce Chemical Co.). Another example is a fluorescent beta-galactosidase substrate that can be used in live cells and is 100-fold more sensitive than GFP (Zlokarnik et. al., 1988, Science 279:85). The skilled artisan by the teachings herein will be amply aware of polynucleotides that may be fused to the immunoglobulin constant region(s) and upon expression produce an enzymatically-active fusion polypeptide comprising the immunoglobulin heavy and/or light chain.
[0060] Such labels may also result in the precipitation of a substrate, for histochemical localization of the antibody, or the label may interact with another detectable component, ands thus be, for example, an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation or a chitin-binding domain.
[0061] Guidance for the selection of the immunoglobulin genes and locations therein in which to fuse the detectable polypeptide(s) of the invention may be performed as follows. As is well known, the antibody molecule is composed of two heavy chains and two light chains. Each chain has a two identical variable regions which bind antigen, and a constant region. The N-terminus of both chains is part of the variable region and the C-terminus is part of the constant region.
[0062] The genomic organization of heavy chain contains a number of repeats of V, D, and J regions upstream of several constant regions. The different constant regions define the eventual antibody class (e.g., IgGl, IgG2a, IgA, etc). During B-cell maturation, a single V, D, and J are
joined to form a single exon. Additionally, late in B-cell development, a single constant region is chosen in a process called "class switching". Each constant region contains a number of exons. After transcription, the VDJ and constant regions are spliced into the mature mRNA.
[0063] To generate the fusion protein of the invention, a polynucleotide encoding the detectable polypeptide is inserted into the constant region, or preferably, is appended to portion of the gene resulting in the expression of the fused polypeptide label on the C-terminus of the constant region of the light and/or heavy chains, optionally with a flexible linker peptide.
[0064] There are two classes of light chains, kappa and lambda. In mice, kappa comprises 95% of antibodies, lambda 5%. Furthermore, there are two forms of each class of the heavy chain — a secreted and a membrane bound form. The membrane bound form is responsible for signaling to the B-cell when it is crosslinked by an antigen and is required for B-cell maturation and antibody production. The two forms result from alternative splicing. Preferably, only the secreted form is modified as described herein. The membrane bound form would be completely wild type, to maintain fidelity of generation of the antibody response.
[0065] Thus, an immune cell with the genetic modifications described herein may secrete immunoglobulin that may have possess a detectable polypeptide label fused in the heavy chain constant region, or a detectable polypeptide label fused in the light chain constant region, or the immunoglobulin may have both a heavy and light chain fusion component. Moreover, each detectable label may be a single detectable label or a plurality of labels, in tandem or not, optionally separated from the immunoglobulin poition of the polypeptide by one or more linker sequences. The label on the heavy chain may be the same or different from that on the light chain, for immunoglobulins that have both heavy and light chains as fusion products. Although the placement of the detectable label is preferably on or near the C-terminus, the fused label(s) may be at any position(s) with does not detract from the ability of the immunoglobulin to interact with and bind to its target antigen. The invention herein embraces any and all variations in the position, placement, linkers, and number of fused peptides or polypeptides, with the object of the invention to provide at least one detectable label on an immunglobulin molecule generated by exposure of an animal or immune cell with the aforementioned genetic modification to any immunogen capable of eliciting secretion of an antibody directed thereto.
[0066] As described above, a mammalian organism, such as a mouse, a rat, a rabbit, a goat, a cow, a donkey, a monkey, a sheep, a pig, or a horse, may be provided with the genetic modification as described herein. Example 4 below demonstrates the invention using mice, in which endogenous production of fluorescent antibodies is shown. Exposure of the animal to a preselected immunogen will elicit an antibody response, the secreted antibodies having the detectable label(s) present in every antibody molecule. For production of polyclonal antibodies, antiserum from the immunized animals may be collected, the antibodies purified if desired, for subsequent use in such areas as histochemistry, diagnostics, etc.
[0067] If detectably-labeled primary monoclonal antibodies are desired, routine methods may be. followed using an animal, such as a mouse, with the genetic makeup hereindescribed. B-cells secreting the detectably-labeled primary antibodies may be fused for immortalization, and screening and selection for stable antibody-secreting hybridomas obtained by routine methods.
[0068] Of course, detectably-labeled primary anti-idiotype antibodies may be prepared by the foregoing methods, using antibodies as immunogen.
[0069] As mentioned above, the polyclonal and monoclonal antibodies generated by the methods described herein have several advantages, including 1) because the primary antibody is endogenously fluorescent, no secondary antibody or chemical labeling is required. This provides for ease of experimentation, with a wider dynamic range and avoids conjugations to the antibody that may affect affinity; 2) autofluorescent proteins are currently available in several different colors, including blue, cyan, green, yellow, and red, allowing for simultaneous labeling of several antigens, and simultaneous detection by instrumentation capable of discriminating several fluorophores simultaneously. In addition, the availability of two different means for detection, such as but not limited to, a visibly-detectable and enzymatically-detectable marker, provides detectability under a variety of conditions, applicable to various research and diagnostic applications, and also allows for conjugation to a therapeutic agent.
[0070] Introduction of the genetic modification(s) described herein into an embryonic stem cell or other cell type may be achieved by a variety of procedures known in the art. Preferably, the
genetic modification is introduced by a "knock-in" procedure in which the wild-type immunoglobulin gene(s) are replaced by the detectable-label-modified genes. Such procedures may include the use of a bacterial artificial chromosome, as exemplified in Example 2 below, although this example is merely illustrative and non limiting as to procedures for achieving the genetically-modified mammal or mammalian cells of the invention.
[0071] Antigens to which detectable antibodies may be raised in genetically-modified animals or immune cells as described herein are not limited to any particular types or classes of immunogen, and includes those for which a detectable antibody is desirable. Such antigens comprise a vast list. By way of non-limiting example, this includes diagnostic and research reagents for identifying the presence of and/or quantitating various medically-important biomolecules in bodily fluids, biopsy and necropsy samples, for example, all diagnostic tests which employ immunoassay protocols, including ELISA, radioimmunoassay, EMIT, immunofluorescence, fluorescence polarization, and other methods for detecting the interaction between and biomolecule of interest and an antibody thereto. Medical diagnostics include, by way of non- limiting example, assays for autoimmune disorders, cardiovascular disorders, diabetes, endocrine disorders, fungal, bacterial, viral, parasitic, and other infectious agents, hematologic diseases, immunologic diseases, hepatic diseases, oncologic diseases, thyroid diseases, and toxicology and drugs of use and abuse. Moreover, as mentioned above, the ability to discriminate between differently labeled primary antibodies without the need for, and concomitant disintegration of signal, by multiple secondary antibodies, will permit multiple analytes to be measured simultaneously, decreasing the costs and increasing the amount of information available for rendering diagnostic and therapeutic decisions. In the research area, innumerable new and known biomolecules to which antibodies are routinely raised for identifying the location, movement, transport, role, etc., of such new or rediscovered biomolecules in biological processes will be simplifiable, as well as permit the simultaneous and facile monitoring of multiple biomolecules using differently-labeled antibodies to several biomolecules participating in a process. The discussion herein on particular antigens is not intended to be at all limiting but is merely illustrative of some examples of the utility of the invention.
[0072] In another example of the invention, a genetically-modified mammal maybe prepared which responds to immunization with an antigen by the production of chimeric immunoglobulin
molecules capable of reading out a signal or altering the signal produced only on binding with the target antigen. This signal may be, for example, an increase, decrease or change in fluorescence. Such chimeric antibodies may be used in a very simple homogeneous immunoassay in which, on combining with a sample, indicates the presence or extent of the level of the antigen in the sample. Pairs of proteins or peptides capable of undergoing such modulation in fluorescence include FRET pairs, such as described, for example, in U.S. Patent 5,998,204, incorporated herein by reference in its entirety.
[0073] Such chimeric antibodies are prepared by following the methods described herein. In the example wherein the fluorescence is detected, the genes encoding the chains of the secreted immunoglobulin are modified at the polynucleotide level to provide that both a fluorescent peptide or polypeptide, and a fluorescence-quenching or -modulating peptide or polypeptide, are fused into either the heavy immunoglobulin chain or the light immunoglobulin chain in the appropriate position in the genome of the mouse. The positions of integration into the respective immunoglobulin components are such that the proximity of the fluorescent polypeptide and the fluorescence-quenching or -modulating polypeptide in the secreted, whole immunoglobulin molecule, change on binding of the immunoglobulin to its target antigen. This change in proximity alters the interaction between the fluorophore and the quencher or modulator resulting in a modulation in the detectable fluorescence on exposure of the immunoglobulin to its excitation wavelength. Such positions are selected to not alter the ability of the complete immunoglobulin molecule to assemble, be secreted, or bind the antigen. These selections are within the realm of the skilled artisan. Known fluorescent peptides or polypeptides as well as peptides and polypeptides capable of quenching or modulating the fluorescence, such as FRET pairs, are known and can be selected to provide the chimeric immunoglobulin, and mammals capable of producing the immunoglobulin after immunization.
EXAMPLES
[0074] The present invention may be better understood by reference to the following non- limiting Examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.
[0075] Example 1: Secretion of detectably-labeled antibodies
[0076] A rat IgG2A antibody hybridoma which produces a monoclonal antibody reactive against beta-galactosidase was used to determining whether GFP fusion proteins would be correctly assembled, secreted, and recognize antigen. The cDNA of the secreted form of the heavy and light chains against beta-galactosidase were cloned. The polynucleotide sequence encoding GFP was placed in front of the stop codon of both the heavy chain of IgG2A and light kappa chains. The plasmid combinations of 1) non-GFP tagged, 2) IgG2A heavy chain tagged, 3) light chain tagged, and 4) both heavy chain and light chain tagged, were transfected into 293T kidney cells and tested for ability to bind antigen.
[0077] The 293T cells do not express any endogenous antibodies. They were transfected with two expression vectors of combinations of IgG2A and kappa chains against beta-galactosidase: 1) IgG2A and kappa; T) IgG2A and kappa-GFP; 3) IgG2A-GFP and kappa; and 4) IgG2A-GFP and kappa-GFP. The transfected cells will express and assemble and secrete the complete antibody. Forty-eight hours after transfection, the medium was harvested. This contained unpurified antibodies which was used for the experiments below
[0078] Confirmation of the secretion of the detectably-labeled antibody was obtained in several experiments. In one experiment, cells were fed radiolabeled 35S methionine after transfection and newly synthesized proteins were labeled. The secreted proteins were collected. Two fractions were evaluated, one that bound to Protein G and one that bound to beta-galactosidase immobilized on beads. Protein G is a toxin which binds antibodies. As shown in Figure I5 both GFP -tagged and untagged antibodies bound to Protein G and to beta-galactosidase. The affinity and specificity towards beta-galactosidase appears greater. Thus, the antibody recognizes antigen and is correctly folded. When only light chain or heavy chain but not both are transfected, the chains did not bind to either protein G or beta-galactosidase. When examined under the microscope, the beads where bright green, showing that the GFP is correctly folded and fluorescent.
[0079] Example 2: Preparation of genetically-modified (knock-in) animals comprising detectably-labeled immunoglobulin genes
[0080] Knock-in or gene replacement involves replacing an endogenous piece of DNA in the chromosome with a constructed piece of DNA. Thus, the constructed DNA must correctly integrate into the same genetic location as the gene to be replaced. This is distinctly different from transgenic technology where a constructed DNA is randomly introduced into a cell.
[0081] I. Construction of a segment of bacterial plasmid DNA that contains the change of interest and extensive homology to the target. Generation of the IgGl-GFP fusion knock-in construct is described below. The VDJ variable regions of the IgGl constant chain are far upstream (51) of this area. Immediately upstream of this area are the IgM and IgD constant regions. Downstream to this area are the constant regions for IgG2a, IgG2b, IgG3, IgE, and IgA. The exons CHl, CH2 and Gl are spliced together to make the constant region of the secreted form. To make the membrane bound form, CHl, CH2, Gl (except the last 2 amino acids), TDl, and TD2 are spliced together. In the targeting vector, GFP is fused in-frame at the end of the Gl exon with a five- amino-acid linker of Gly-Gly-Ser-Gly-Gly (SEQ ID NO: 2) in-between. The membrane bound form splices out the last two amino acids of Gl and thus the entire GFP. Therefore, GFP will be fused only to the secreted form.
[0082] A bacterial artificial chromosome (BAC) containing the entire IgG region is obtained. The targeting vector contains the 5' homologous region directly PCRed from the BAC. The Gl - GFP fusion is generated by primer overlap extension PCR (Horton et al., 1990; Horton, 1995). A neomycin resistance gene is introduced as a selection marker. This neomycin gene is flanked on each side by a loxP site. Thus, after selection, the gene is deleted by Cre-mediated recombination. This eliminates problems due to the presence of the neomycin gene and its associated promoter (Zou et al., 1993). A 3' homologous region is also PCRed from the BAC. Finally, a toxic gene, diphtheria toxin (DTA) is introduced just outside the area of homology. Homologous recombination between the targeting vector and the targeting region cuts out the toxin gene. Non-homologous random integration events often retain DTA and the cells will be killed (Yagi et al., 1990; Yagi et al., 1993; McCarrick, III et al., 1993).
[0083] After preparation, embryonic stem cells are transfected with the targeting vector and selection with neomycin analog G418 is performed. Clones are screened for correct integration by Southern analysis and PCR. Subsequently, correctly targeted ES cell are injected into
blastocysts and implanted into mothers. The blastocysts develop into chimeric mice, where some cells are developed from the injected ES cells. The chimeras are used to parent heterozygote mice. Two heterozygous mice are then parented to produce homozygous mice.
[0084] The mouse IgGl heavy chain and kappa light chains have been previously targeted for gene replacement. In those cases, the constant chain was replaced with human constant chains and the resulting mice generated humanized antibodies (Zou et al., 1993; Zou et al., 1994).
[0085] Production of Monoclonal Antibodies. Mice as prepared above are inoculated with the antigen of interest. After several weeks, the antibody production against the antigen is screened, as traditionally done with an ELISA, where the antigen is immobilized, the mouse serum is added, and an enzyme-linked secondary antibody against the primary is added. The presence of enzymatic activity indicates that the mouse has produced specific antibodies. Since here, the antibodies are already fluorescent, an ELISA is unnecessary and measurement of bound fluorescence is sufficient. Fusion of splenocytes from a positive mouse with myeloma cells is used to produce immortalized antibody-producing cells, following standard protocols. Further screening of colonies can be performed using simple fluorescence measurements.
[0086] Antibody may be produced in quantity by growth of cell-hybrids, following standard protocols.
[0087] Example 3: Homogeneous immunoassays using detectably-labeled antibodies from a genetically-modified mouse
[0088] In a further example of the methods described in Example 2, above, a genetically- modified mouse may be prepared which responds to immunization with an antigen by the production of chimeric immunoglobulin molecules capable of reading out a signal only on binding with the target antigen. Such chimeric antibodies may be used in a very simple homogeneous immunoassay in which, on combining with a sample, indicates the presence or extent of the level of the antigen in the sample. Such chimeric antibodies are prepared by following the methods herein. Both a fluorescent peptide or polypeptide, and a fluorescence- quenching peptide or polypeptide, are fused into either the heavy immunoglobulin chain or the light immunoglobulin chain in the appropriate position in the genome of the mouse. Such pairs
may include FRET pairs or proteins, such as described, for example, in U.S. Patent 5,998,204, incorporated herein by reference in its entirety. The positions of integration into the respective immunoglobulin components are such that the proximity of the fluorescent polypeptide and the fluorescence-quenching polypeptide change on binding of the immunoglobulin to its target antigen. Such positions also do not alter the ability of the complete immunoglobulin molecule to assemble, be secreted, or bind the antigen. Both the fluorescent and the fluorescence-quenching protein or peptides may be fused into the same immunoglobulin component, at positions wherein antigen binding induces a conformational change and thus a proximity change among the pair and attendant modulation of fluorescence.
[0089] Examples of fluorescent peptides and proteins are described above. Suitable pairs, for example, include a blue-shifted GFP mutant P4-3 (Y66H/Y145F) as the donor, and an improved green mutant S65T can respectively serve as a donor and an acceptor for fluorescence resonance energy transfer (FRET; Tsien et al, 1993, Trends Cell Biol. 3:242-245). A genetically-modified mouse expressing antibodies with these modifications was immunized with human chorionic gonadotropin (hCG). The fluorescence of antibodies produced by this mouse was increased upon binding to hCG. This reagent was used in a simplified assay in an automated fluorescence-based instrument for determining pregnancy among a large battery of other diagnostic tests on blood and urine samples.
[0090] Example 4: Kappa-GFP knock-in mice produce fluorescent endogenous antibodies [0091] Kappa-GFP knock-in mice were prepared in accordance with the methods described in Example 2, above. At 8 weeks of age, animals were bled and serum was incubated with Protein A/G beads, to which antibodies in the serum bind. As shown in Figure 2, under fluorescence illumination the beads showed the characteristic fluorescence of GFP (Figure 2A), whereas serum from wild-type mice incubated with Protein A/G beads did not (Figure 2B). Thus, the mice produced fluorescently-labeled, endogenous immunoglobulin molecules, comprising kappa- GFP, fluorescent light chains.
[0092] Example 5: Confirmation of genotype using PCR for kappa and GFP
[0093] Figure 3 shows the results of PCR amplification using primers from up- and down-stream of the section of the kappa light chain where the GFP was targeted (Figure 3A), or using GFP
primers (Figure 3B), from DNA extracts from a number of mice prepared in accordance with the present invention. The segment amplified from wild type kappa light chains is the smallest and runs the fastest on the gel (as indicated). The segment amplified with the GFP insert is larger and migrates slower.
[0094] In Figure 3 A, using the kappa primers, lane 2 has only the faster moving product and is therefore from a mouse that is homozygous for wild-type kappa light chain. Lanes 3, 5, and 7-12 have both products, which indicates that the mice are heterozygous. Lanes 1, 4, and 6 only have the slower moving product indicating that they are homozygous for the kappa with the inserted GFP.
[0095] Figure 3B shows using primers from the GFP coding region that lane 2 was negative for GFP, consistent with the observation that this mouse did not produce a PCR product from kappa- GFP. Lanes 1 and 2-12 were positive for GFP, consistent with the results from the top panel.
[0096] The present invention is not to be limited in scope by the specific embodiments describe herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
[0097] It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.
[0098] Various publications are cited herein, as described below.
[0099] Horton,R.M. (1995). PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes. MoI. Biotechnol. 3, 93-99.
[0100] Horton,R.M., Cai,Z.L., Ho,S.N., and Pease,L.R. (1990). Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques 8, 528-535.
[0101] McCarrick,J.W.5 III, Parnes,J.R., Seong,R.H., Solter-D., and Knowles,B.B. (1993). Positive-negative selection gene targeting with the diphtheria toxin A- chain gene in mouse embryonic stem cells. Transgenic Res. 2, 183-190.
[0102] Yagi,T., Ikawa,Y., Yoshida,K., Shigetani,Y., Takeda,N.5 Mabuchi,!, Yamamoto,T., and Aizawa,S. (1990). Homologous recombination at c-fyn locus of mouse embryonic stem cells with use of diphtheria toxin A-fragment gene in negative selection. Proc. Natl. Acad. Sci. U. S. A 87, 9918-9922.
[0103] Yagi,T., Nada,S., Watanabe,N., Tamemoto,H., Kohmura,N., Ikawa,Y., and Aizawa,S. (1993). A novel negative selection for homologous recombinants using diphtheria toxin A fragment gene. Anal. Biochem. 214, 77-86.
[0104] Zou,Y.R., Gu5H., and Rajewsky,K. (1993). Generation of a mouse strain that produces immunoglobulin kappa chains with human constant regions [see comments]. Science 262, 1271- 1274.
[0105] Zou,Y.R., Muller,W., Gu,H., and Rajewsky,K. (1994). Cre-loxP-mediated gene replacement: a mouse strain producing humanized antibodies. Curr. Biol. 4, 1099-1103.
Claims
1. A genetically-modified non-human mammal containing a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin molecule comprising two heavy chains and two light chains, and a nucleic acid encoding at least one detectable protein, wherein said non-human mammal is capable of expressing said at least one detectable protein fused with said immunoglobulin molecule wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises said at least one detectable protein.
2. The genetically-modified non-human mammal of claim 1 wherein said one detectable protein encoded by the fusion polynucleotide is present at the C-terminus of the gene product of said fusion polynucleotide.
3. The genetically-modified non-human mammal of claim 2 wherein said nucleic acid encoding said one detectable protein present at the C-terminus of the gene product of said fusion polynucleotide is located in exon Gl.
4. The genetically-modified non-human mammal of claim 1 wherein said one detectable protein is present at the C-terminus of the gene product of said fusion polynucleotide with a flexible linker peptide located between the one detectable protein and the immunoglobulin molecule.
5. The genetically-modified non-human mammal of claim 1 wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises one detectable protein in the heavy chain of said antibody.
6. The genetically-modified non-human mammal of claim 1 wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises one detectable protein in the light chain of said antibody.
7. The genetically-modified non-human mammal of claim 1 wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises at least one detectable protein in the heavy chain and at least one detectable protein in the light chain of said antibody.
8. The genetically-modified non-human mammal of claim 1 wherein the one detectable protein is capable of quenching fluorescence.
9. The genetically-modified non-human mammal of claim 1 wherein the at least one detectable protein is an autofluorescent protein, a luminescent protein, a visibly-detectable protein, an enzymatically active protein, or a protein capable of interacting with another molecule to produce a detectable product.
10. The genetically-modified non-human mammal of claim 9 wherein said one detectable protein is an autofluorescent protein.
11. The genetically-modified non-human mammal of claim 9 wherein said one detectable protein is a combination of an autofluorescent protein and an enzymatically-active protein.
12. The genetically-modified non-human mammal of claim 11 wherein said one detectable protein is a combination of green fluorescent protein and alkaline phosphatase.
13. A genetically-modified immune cell having a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin molecule comprising two heavy chains and two light chains, a nucleic acid encoding at least one detectable protein, and a nucleic acid encoding a flexible linker peptide located between the nucleic acid encoding the immunoglobulin molecule and the nucleic acid encoding the at least one detectable protein, and wherein said immune cell is capable of expressing at least one detectable protein fused with said immunoglobulin molecule, with the flexible linker peptide between the immunoglobulin molecule and the at least one detectable protein, wherein antibodies secreted by said genetically-modified immune cell comprise said at least one detectable protein.
14. The genetically-modified immune cell of claim 13 wherein said one detectable protein is present at the C-terminus of the gene product of said fusion polynucleotide.
15. The genetically-modified immune cell of claim 13, wherein said nucleic acid encoding said one detectable protein present at the C-terminus of the gene product of said fusion polynucleotide is located in exon Gl.
16. The genetically-modified immune cell of claim 13 wherein an antibody secreted by said immune cell comprises one detectable protein in the heavy chain of said antibody.
17. The genetically-modified immune cell of claim 13 wherein an antibody secreted by said genetically-modified immune cells comprises one detectable protein in the light chain of said antibody.
18. The genetically-modified immune cell of claim 13 wherein an antibody secreted by said genetically-modified immune cells comprises one detectable protein in the heavy chain and one detectable protein in the light chain of said antibody.
19. The genetically-modified immune cell of claim 13 wherein the one detectable protein is capable of quenching fluorescence.
20. The genetically-modified immune cell of claim 13 wherein the at least one detectable protein is an autofluorescent protein or peptide, a luminescent protein, a visibly-detectable protein or peptide, an enzymatically active protein or peptide, or a protein or peptide capable of interacting with another molecule to produce a detectable product.
21. The genetically-modified immune cell of claim 20 wherein the one detectable protein is an autofluorescent protein.
22. The genetically-modified immune cell of claim 20 wherein said one detectable protein is a combination of an autofluorescent protein and an enzymatically-active protein.
23. The genetically-modified immune cell of claim 22 wherein said one detectable protein is a combination of green fluorescent protein and alkaline phosphatase.
24. A hybridoma comprising the genetically-modified immune cell of claim 13.
25. A genetically-modified non-human mammal capable of producing a detectably-labeled antibody in response to immunization by an antigen, the genome of said non-human mammal comprising a fusion polynucleotide comprising a nucleic acid encoding at least one detectable protein and a nucleic acid encoding an immunoglobulin molecule comprising two heavy chains and two light chains, wherein an antibody secreted by an immune cell of said genetically- modified non-human mammal comprises said at least one detectable protein.
26. The genetically modified non-human mammal of claim 9 or the genetically modified immune cell of claim 20, wherein said protein capable of interacting with another molecule to produce a detectable product is selected from the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation, or a chitin- binding domain, or any combination thereof, and wherein said protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of said detectable product.
27. A genetically-modified non-human mammal containing a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, and a nucleic acid encoding at least two detectable proteins, wherein said non-human mammal is capable of expressing at least two detectable proteins fused with said immunoglobulin component wherein an antibody secreted by an immune cell of said genetically- modified non-human mammal comprises said at least two detectable proteins.
28. The genetically-modified non-human mammal of claim 27 wherein said at least two detectable proteins encoded by the fusion polynucleotide are present at the C-terminus of the gene product of said fusion polynucleotide.
29. The genetically-modified non-human mammal of claim 28 wherein said nucleic acid encoding said at least two detectable proteins present at the C-terminus of the gene product of said fusion polynucleotide is located in exon Gl .
30. The genetically-modified non-human mammal of claim 27 wherein said at least two detectable proteins are present at the C-terminus of the gene product of said fusion polynucleotide with a flexible linker peptide located between the at least two detectable proteins and the immunoglobulin component.
31. The genetically-modified non-human mammal of claim 27 wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises at least two detectable proteins in the heavy chain of said antibody.
32. The genetically-modified non-human mammal of claim 27 wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises at least two detectable proteins in the light chain of said antibody.
33. The genetically-modified non-human mammal of claim 27 wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises at least two detectable proteins in the heavy chain and at least two detectable proteins in the light chain of said antibody.
34. The genetically-modified non-human mammal of claim 27 wherein one of the at least two detectable proteins is capable of quenching fluorescence.
35. The genetically-modified non-human mammal of claim 27 wherein at least one of the at least two detectable proteins is an autofluorescent protein, a luminescent protein, a visibly-detectable protein, an enzymatically active protein, or a protein capable of interacting with another molecule to produce a detectable product.
36. The genetically-modified non-human mammal of claim 35 wherein said at least one of the at least two detectable proteins is an autofluorescent protein.
37. The genetically-modified non-human mammal of claim 35 wherein said at least one detectable protein is a combination of an autofluorescent protein and an enzymatically-active protein.
38. The genetically-modified non-human mammal of claim 37 wherein said at least one detectable protein is a combination of green fluorescent protein and alkaline phosphatase.
39. A genetically-modified immune cell having a vector comprising a fusion polynucleotide, said fusion polynucleotide comprising a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, a nucleic acid encoding at least two detectable proteins, and a nucleic acid encoding a flexible linker peptide located between the nucleic acid encoding the immunoglobulin component and the nucleic acid encoding the at least two detectable proteins, and wherein said immune cell is capable of expressing at least two detectable proteins fused with said immunoglobulin component, with the flexible linker peptide between the immunoglobulin component and the at least two detectable proteins, wherein antibodies secreted by said genetically-modified immune cell comprise said at least two detectable proteins.
40. The genetically-modified immune cell of claim 39 wherein said at least two detectable proteins are present at the C-terminus of the gene product of said fusion polynucleotide.
41. The genetically-modified immune cell of claim 39, wherein said nucleic acid encoding said at least two detectable proteins present at the C-terminus of the gene product of said fusion polynucleotide is located in exon Gl.
42. The genetically-modified immune cell of claim 39 wherein said immunoglobulin heavy chain is selected from the group consisting of IgG, IgM, IgD and IgA.
43. The genetically-modified immune cell of claim 39 wherein an antibody secreted by said immune cell comprises at least two detectable proteins in the heavy chain of said antibody.
44. The genetically-modified immune cell of claim 39 wherein an antibody secreted by said genetically-modified immune cells comprises at least two detectable proteins in the light chain of said antibody.
45. The genetically-modified immune cell of claim 39 wherein an antibody secreted by said genetically-modified immune cells comprises at least two detectable proteins in the heavy chain and at least two detectable proteins in the light chain of said antibody.
46. The genetically-modified immune cell of claim 39 wherein one of the at least two detectable proteins is capable of quenching fluorescence.
47. The genetically-modified immune cell of claim 39 wherein at least one of the at least two detectable proteins is an autofiuorescent protein or peptide, a luminescent protein, a visibly- detectable protein or peptide, an enzymatically active protein or peptide, or a protein or peptide capable of interacting with another molecule to produce a detectable product.
48. The genetically-modified immune cell of claim 47 wherein said at least one of the at least two detectable proteins is an autofiuorescent protein.
49. The genetically-modified immune cell of claim 47 wherein said at least one detectable protein is a combination of an autofluorescent protein and an enzymatically-active protein.
50. The genetically-modified immune cell of claim 49 wherein said at least one detectable protein is a combination of green fluorescent protein and alkaline phosphatase.
51. A hybridoma comprising the genetically-modified immune cell of claim 39.
52. A genetically-modified non-human mammal capable of producing a detectably-labeled antibody in response to immunization by an antigen, the genome of said non-human mammal comprising at least one fusion polynucleotide comprising a nucleic acid encoding at least two detectable proteins and a nucleic acid encoding an immunoglobulin component selected from the group consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof, wherein an antibody secreted by an immune cell of said genetically-modified non-human mammal comprises said at least two detectable proteins.
53. The genetically modified non-human mammal of either one of claims 9 or 35, or the genetically modified immune cell of either one of claims 20 or 47, wherein said protein capable of interacting with another molecule to produce a detectable product is selected from the group consisting of an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, a consensus sequence for biotinylation, or a chitin-binding domain, or any combination thereof, and wherein said protein capable of interacting with another molecule to produce a detectable product may also be used to facilitate purification of said detectable product or conjugation of a therapeutic.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2006/024592 WO2007149097A1 (en) | 2006-06-23 | 2006-06-23 | Animals, cells and methods for production of detectably-labeled antibodies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2006/024592 WO2007149097A1 (en) | 2006-06-23 | 2006-06-23 | Animals, cells and methods for production of detectably-labeled antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007149097A1 true WO2007149097A1 (en) | 2007-12-27 |
Family
ID=38833713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/024592 WO2007149097A1 (en) | 2006-06-23 | 2006-06-23 | Animals, cells and methods for production of detectably-labeled antibodies |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007149097A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109596581A (en) * | 2018-11-19 | 2019-04-09 | 江苏大学 | Utilize bovine serum albumin -- the purposes of electrum nano-cluster detection of alkaline phosphatase |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6570061B1 (en) * | 1992-08-25 | 2003-05-27 | Klaus Rajewsky | Targeted replacement of an immunoglobulin gene without endogenous and selectable residual sequences in mice |
US6673573B2 (en) * | 1997-04-22 | 2004-01-06 | Gsf-Forschungszentrum Fur Umwelt Und Gesundheit | Expression of immunoglobulin-cytokine fusion proteins in malignant B cells |
US20040250307A1 (en) * | 2000-06-19 | 2004-12-09 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
US6972198B2 (en) * | 1999-02-26 | 2005-12-06 | Cyclacel, Ltd. | Methods and compositions using protein binding partners |
US7091396B1 (en) * | 2000-10-17 | 2006-08-15 | The Rockefeller University | Animals, cells and methods for production of detectably-labeled antibodies |
-
2006
- 2006-06-23 WO PCT/US2006/024592 patent/WO2007149097A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6570061B1 (en) * | 1992-08-25 | 2003-05-27 | Klaus Rajewsky | Targeted replacement of an immunoglobulin gene without endogenous and selectable residual sequences in mice |
US6673573B2 (en) * | 1997-04-22 | 2004-01-06 | Gsf-Forschungszentrum Fur Umwelt Und Gesundheit | Expression of immunoglobulin-cytokine fusion proteins in malignant B cells |
US6972198B2 (en) * | 1999-02-26 | 2005-12-06 | Cyclacel, Ltd. | Methods and compositions using protein binding partners |
US20040250307A1 (en) * | 2000-06-19 | 2004-12-09 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
US7091396B1 (en) * | 2000-10-17 | 2006-08-15 | The Rockefeller University | Animals, cells and methods for production of detectably-labeled antibodies |
US20060288430A1 (en) * | 2000-10-17 | 2006-12-21 | Simon Sanford M | Animals, cells and methods for production of detectably-labeled antibodies |
Non-Patent Citations (2)
Title |
---|
CASEY ET AL.: "Green Fluorescent Antibodies: Novel in Vitro Tools", PROTEIN ENGINEERING, vol. 13, no. 6, June 2000 (2000-06-01), pages 445 - 452 * |
PEIPP ET AL.: "Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications", J. IMMUN. METH., vol. 285, February 2004 (2004-02-01), pages 265 - 280 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109596581A (en) * | 2018-11-19 | 2019-04-09 | 江苏大学 | Utilize bovine serum albumin -- the purposes of electrum nano-cluster detection of alkaline phosphatase |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2644684C2 (en) | Antibodies with built in the light circuit by hystidine and genetically modified excellent from human animals for their obtaining | |
US7060869B2 (en) | Fluorescent protein sensors for detection of analytes | |
RU2694728C2 (en) | Antibodies with histidine built in light chains and genetically modified animals different from humans for their production | |
US6627449B1 (en) | Fluorescent protein sensors for measuring the pH of a biological sample | |
EP0970199B1 (en) | Fluorescent protein sensors for detection of analytes | |
US9332742B2 (en) | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same | |
US8952215B2 (en) | Antibody-producing transgenic silkworms and methods for producing the same | |
HUE026229T2 (en) | Common light chain mouse | |
CA3125380A1 (en) | Genetically modified non-human animals with humanized immunoglobulin locus | |
US11997994B2 (en) | Genetically modified non-human animals with common light chain immunoglobulin locus | |
US20060288430A1 (en) | Animals, cells and methods for production of detectably-labeled antibodies | |
WO2007149097A1 (en) | Animals, cells and methods for production of detectably-labeled antibodies | |
US6040176A (en) | Antibodies to ICAM-related protein | |
WO2008094316A2 (en) | Novel branchiostoma derived fluorescent proteins | |
US20100205679A9 (en) | Animals, cells and methods for production of detectably-labeled antibodies | |
US20030024001A1 (en) | Knock in transgenic mammal containing a non-functional N-terminus of Kv beta 1.1 subunit | |
US11878065B2 (en) | Reporter protein fused antibodies | |
GB2406337A (en) | A reporter construct expressing a secretable and excretable reporter protein | |
US20060105323A1 (en) | Multi-reporter gene model for toxicological screening | |
US20240023526A1 (en) | Heavy chain-only antibodies | |
US20210009670A1 (en) | Nucleic acid molecules and applications thereof in human antibody | |
CN118056006A (en) | Transgenic rodents for cell line identification and enrichment | |
CN118339300A (en) | Animal model for producing humanized antibody and construction method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06785494 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06785494 Country of ref document: EP Kind code of ref document: A1 |